sheenayam的个人主页 - 老虎社区

sheenayam

sheenayam

暂无个人介绍

IP属地：未知

171关注

23粉丝

0主题

0勋章

2022-01-21

加油恒瑞

那些投资恒瑞医药的人，到底在坚持什么？

2022-01-17

Interesting

抱歉，原内容已删除

2022-01-16

Hengrui, steady, hope that more good news will come your way!!

恒瑞医药(600276.SH)子公司SHR-1314注射液获药物临床试验批准

2022-01-16

Congrats for the good news!

恒瑞医药(600276.SH)：恒曲获批开展治疗恶性肿瘤化疗所致血小板减少症Ⅲ期临床试验

2022-01-16

Interesting...

【北向资金大单买入报告】恒瑞医药获净卖出7.77亿元

2022-01-16

Wow...

北水连续第8日加仓美团，今日再大幅买入超8亿港元；南水抛售恒瑞医药

2022-01-16

Good news!!!

恒瑞医药(600276.SH)SHR8008胶囊的药品上市许可申请获药监局受理

2021-11-29

Like

November jobs report: What to know this week

2021-11-15

Interesting... Will included in my watchlist

抱歉，原内容已删除

2021-11-12

Good job

CRISPR Therapeutics Q3 Sales $300.00K Up From $148.00K YoY

2021-11-11

Will see how the result goes in next quarter...

Why Palantir Stock Dropped on Wednesday

2021-11-08

Steady

Buffett’s Berkshire Appetite Surpasses Cash Spent on Apple Stock

2021-11-08

Emmm....

抱歉，原内容已删除

2021-10-31

Alright!

抱歉，原内容已删除

2021-10-27

Looking forward

抱歉，原内容已删除

2021-10-26

Interesting

抱歉，原内容已删除

2021-10-26

Shall see

抱歉，原内容已删除

2021-10-26

Looking forward

抱歉，原内容已删除

2021-10-25

Let's go!!!

Tesla shares rose more than 4% in premarket trading.

2021-10-25

Steady

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3579743164156658","uuid":"3579743164156658","gmtCreate":1617160927098,"gmtModify":1704447520697,"name":"sheenayam","pinyin":"sheenayam","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":23,"headSize":171,"tweetSize":234,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":"60.51%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":630163977,"gmtCreate":1642743044396,"gmtModify":1642743044663,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"加油恒瑞","listText":"加油恒瑞","text":"加油恒瑞","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630163977","repostId":"2204086873","repostType":2,"repost":{"id":"2204086873","kind":"highlight","weMediaInfo":{"introduction":"小北读财报，带你选白马。","home_visible":1,"media_name":"小北读财报","id":"1061096740","head_image":"https://static.tigerbbs.com/25c953854500faba5b1551a754dd76c9"},"pubTimestamp":1642496254,"share":"https://www.laohu8.com/m/news/2204086873?lang=&edition=full","pubTime":"2022-01-18 16:57","market":"us","language":"zh","title":"那些投资恒瑞医药的人，到底在坚持什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2204086873","media":"小北读财报","summary":"我想，投资恒瑞医药的人应该都是这么认为的，只是可能没有投资在好的价格上。2022年1月13日，随着恒瑞医药在投资互动平台中回复2021年前三季度企业业绩增速放缓原因，恒瑞医药便又迎来了接连几日的下跌，昨日甚至进入到了沪股通成交榜，被净卖出了7252.92万元。（注明：药品红字部分指恒瑞医药已上市的7款创新药，恒瑞医药目前共有10款创新药。","content":"<html><body><p><strong><span>巴菲特曾经说过对于质优股永远不卖，</span></strong>他曾说，如果你给我1000亿美元用以交换<a href=\"https://laohu8.com/S/KO\">可口可乐</a>这种饮料在世界上的领先权，我会把钱还给你，并对你说‘这可不成’。<strong><span>但巴菲特也会说，</span></strong>当人们忘记“二加二等于四”这种最基本的常识时，就该是脱手离场的时候了，<a href=\"https://laohu8.com/S/BRK.A\">伯克希尔</a>的保险子公司也曾通过套利获得了异常巨大的利润。</p><p><strong><span>如果将巴菲特的投资原则提炼一下的话，那就是对于有高的竞争壁垒（或者说特许经营权）的企业不会卖出，但也会买卖市场上的价格与价值出现偏离的股票。</span></strong></p><p>那这时候我就想到了<strong><span><a href=\"https://laohu8.com/S/600276\">恒瑞医药</a></span></strong>，它是属于巴菲特认为的哪一类呢，而显然，在我看来，<strong><span>它一定是属于有高竞争壁垒的前者。</span></strong>我想，投资恒瑞医药的人应该都是这么认为的，只是可能没有投资在好的价格上。</p><p>话不多说，好久没跟踪恒瑞医药了，我们来看看它现在怎么样了。</p><p><strong><span>一、业绩增速放缓仍然刺激着股价短期走势</span></strong></p><p>根据业绩预增披露原则，近期已有不少企业陆陆续续披露了业绩预增报告，但对于恒瑞医药来说，今年的业绩预增报告肯定是没戏了（净利润同比增长50%或下降50%以上）。</p><p><strong><span>2022年1月13日，随着恒瑞医药在投资互动平台中回复2021年前三季度企业业绩增速放缓原因，恒瑞医药便又迎来了接连几日的下跌，</span></strong>昨日甚至进入到了沪股通成交榜，被净卖出了7252.92万元。许久不见，大家还是那么情绪化。</p><div><img img_height=\"397\" img_width=\"640\" inline=\"0\" src=\"https://static.tigerbbs.com/972a9c440ebf4d03b7e03db42565ed92\"/></div><p><strong><span>但显然，这些都不能证明恒瑞医药短期的基本面又发生了大的变动，</span></strong>只能说股价因为资金流入上涨、流出下跌是很正常的事情。</p><p>而且早在2021年，恒瑞医药二季度、三季度业绩便呈现出明显下滑趋势，但它的前十大流通股股东，除了香港中央结算有限公司减持了6.9%之外，其他机构均处于不变甚至增持趋势。</p><p><strong><span>对于恒瑞医药来说，近两年医保谈判以及仿制药集采都因药品单价的大幅下跌而给企业业绩带来不小压力。</span></strong>大产品PD-1于2020年年末加入医保降幅近85%，紧接着在2021年年末又有四款药，其中包括三款创新药，首次纳入了国家医保目录；</p><p><strong><span>除此之外，恒瑞医药一共参与了四次仿制药全国集采，</span></strong>第二次～第五次集采一次都没落下，而且按集采相关规定来看，药品集采对业绩影响一般会在半年后兑现，相关药品收入免不了下降50%。</p><p>所以衡量来看，在2021年恒瑞医药业绩没有明显起色的背景下，考虑2021的集采和谈判，我们似乎认为恒瑞医药2022业绩增长仍有着不小压力。</p><p><strong><span>但如果仅仅是这么考虑，我们可能和那些情绪化的投资者没什么区别，而且有点想当然。</span></strong></p><div><img img_height=\"446\" img_width=\"640\" inline=\"0\" src=\"https://static.tigerbbs.com/cb885e7eaa274609b4bf510bba5f8c45\"/></div><p><em>（注明：药品红字部分指恒瑞医药已上市的7款创新药，恒瑞医药目前共有10款创新药。）</em></p><p><strong><span>二、恒瑞医药2022年业绩增长有何支撑？</span></strong></p><p><strong><span>因为细细追究来看，我们会发现，事情并没有那么悲观，</span></strong>对于恒瑞医药来说，这是一个不断进化的过程，且净利率端还有当前较大的研发压力，恒瑞医药厚积薄发还是有希望的。</p><p><strong><span>1、仿制药集采虽会扩容，但“新药”上市速度在加快</span></strong></p><p>虽然2021年上半年第三次集采的六款仿制药收入下降了57%，但整体来看，恒瑞医药的收入仍然是在增长的，<strong><span>这一方面和我们一直说道的创新药上市密切相关，另一方面是因为“新的”仿制药也在不断上市。</span></strong></p><p>即2021年上半年恒瑞医药共有<strong><span>14款</span></strong>药品获得药（产）品注册批件，其中有近三分之二都是仿制药；相对应的2020年全年，恒瑞医药取得创新药制剂生产批件为<strong><span>6个</span></strong>、仿制药制剂生产批件也仅有<strong><span>5个</span></strong>，<strong><span>创新药和仿制药上市速度都在加快。</span></strong></p><p>同时，由2022年新一年的集采计划目标，按品种数量来看，2022年将实施的两次集采的规模或不会小于前五次。</p><p><strong><span>所以对于恒瑞医药来说，虽然已知集采会不断深化，但恒瑞医药有能力维持着仿制药的收入规模不会出现突然大幅度的下滑。实现业绩平滑是恒瑞医药尽快转型的一个重要方式。</span></strong></p><div><img img_height=\"266\" img_width=\"640\" inline=\"0\" src=\"https://static.tigerbbs.com/b60b164dcbec4dc0a1605db34816886c\"/></div><p><strong><span>2、创新药拐点可能要早于业绩拐点</span></strong></p><p>恒瑞医药目前的创新药销售情况就好比狗熊掰棒子，刚上市一个产品可能不到半年就加入医保谈判降价了，<strong><span>但追究下去的话我们会发现要不是前前后后这些创新药撑着局面，恒瑞医药怎么可能维持着业绩的稳定。</span></strong></p><p>2021年上半年恒瑞医药创新药收入占比为39.15%，收入规模同比增长了43.8%，而这半年创新药新上市产品有1种，2020年新加入医保的为1种，一共有8款创新药；</p><p>2021年下半年，恒瑞医药又新上市了两款创新药，同时在医保内的创新药数量增加了3种（均为谈判），一共有10款创新药，因此从“结构”和规模上看都没有太大问题。</p><p><strong><span>值得一提的是，恒瑞医药新上市的两款创新药，达尔西利、恒格列净分别是首个国产CDK4/6抑制剂、首个国产SGLT-2抑制剂，二者研发投入累计超过了6.37亿元，相当于PD-1 40%的研发规模，不容小觑。</span></strong></p><p>因此，对于恒瑞医药来说，当前研发进程仍在持续加快，作为净利润端的一大影响因素，研发费用率的提升甚至比销售费用率的提升以及毛利率的下降幅度还要大，<strong><span>但没有前者的投入，又怎么能带来销售费用率和毛利率的正向改善，这是一个一比二的关系。</span></strong></p><p><strong><span>三、总结一下</span></strong></p><p><strong><span>总的来看，我们对于恒瑞医药的看法始终没有改变，</span></strong>虽然前期因为企业参与集采以及医保降价，基本面发生了一些变化，但股价下挫最主要的原因还在于前期预期太高了，如果之前股价没有透支未来好几年的情况或许股价下跌幅度会小点。</p><p>展望未来，恒瑞医药见到希望的曙光可能不需要太久，既然2021年不行，那我们就等2022年，如果再出现价格更低的情况反而也是好的，但在抄底之前，我们要做好充分的准备！（比如说现金流折现算一下乐观或悲观情况下，恒瑞医药的价值。）</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>那些投资恒瑞医药的人，到底在坚持什么？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n那些投资恒瑞医药的人，到底在坚持什么？\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1061096740\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/25c953854500faba5b1551a754dd76c9);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">小北读财报 </p>\n<p class=\"h-time\">2022-01-18 16:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><span>巴菲特曾经说过对于质优股永远不卖，</span></strong>他曾说，如果你给我1000亿美元用以交换<a href=\"https://laohu8.com/S/KO\">可口可乐</a>这种饮料在世界上的领先权，我会把钱还给你，并对你说‘这可不成’。<strong><span>但巴菲特也会说，</span></strong>当人们忘记“二加二等于四”这种最基本的常识时，就该是脱手离场的时候了，<a href=\"https://laohu8.com/S/BRK.A\">伯克希尔</a>的保险子公司也曾通过套利获得了异常巨大的利润。</p><p><strong><span>如果将巴菲特的投资原则提炼一下的话，那就是对于有高的竞争壁垒（或者说特许经营权）的企业不会卖出，但也会买卖市场上的价格与价值出现偏离的股票。</span></strong></p><p>那这时候我就想到了<strong><span><a href=\"https://laohu8.com/S/600276\">恒瑞医药</a></span></strong>，它是属于巴菲特认为的哪一类呢，而显然，在我看来，<strong><span>它一定是属于有高竞争壁垒的前者。</span></strong>我想，投资恒瑞医药的人应该都是这么认为的，只是可能没有投资在好的价格上。</p><p>话不多说，好久没跟踪恒瑞医药了，我们来看看它现在怎么样了。</p><p><strong><span>一、业绩增速放缓仍然刺激着股价短期走势</span></strong></p><p>根据业绩预增披露原则，近期已有不少企业陆陆续续披露了业绩预增报告，但对于恒瑞医药来说，今年的业绩预增报告肯定是没戏了（净利润同比增长50%或下降50%以上）。</p><p><strong><span>2022年1月13日，随着恒瑞医药在投资互动平台中回复2021年前三季度企业业绩增速放缓原因，恒瑞医药便又迎来了接连几日的下跌，</span></strong>昨日甚至进入到了沪股通成交榜，被净卖出了7252.92万元。许久不见，大家还是那么情绪化。</p><div><img img_height=\"397\" img_width=\"640\" inline=\"0\" src=\"https://static.tigerbbs.com/972a9c440ebf4d03b7e03db42565ed92\"/></div><p><strong><span>但显然，这些都不能证明恒瑞医药短期的基本面又发生了大的变动，</span></strong>只能说股价因为资金流入上涨、流出下跌是很正常的事情。</p><p>而且早在2021年，恒瑞医药二季度、三季度业绩便呈现出明显下滑趋势，但它的前十大流通股股东，除了香港中央结算有限公司减持了6.9%之外，其他机构均处于不变甚至增持趋势。</p><p><strong><span>对于恒瑞医药来说，近两年医保谈判以及仿制药集采都因药品单价的大幅下跌而给企业业绩带来不小压力。</span></strong>大产品PD-1于2020年年末加入医保降幅近85%，紧接着在2021年年末又有四款药，其中包括三款创新药，首次纳入了国家医保目录；</p><p><strong><span>除此之外，恒瑞医药一共参与了四次仿制药全国集采，</span></strong>第二次～第五次集采一次都没落下，而且按集采相关规定来看，药品集采对业绩影响一般会在半年后兑现，相关药品收入免不了下降50%。</p><p>所以衡量来看，在2021年恒瑞医药业绩没有明显起色的背景下，考虑2021的集采和谈判，我们似乎认为恒瑞医药2022业绩增长仍有着不小压力。</p><p><strong><span>但如果仅仅是这么考虑，我们可能和那些情绪化的投资者没什么区别，而且有点想当然。</span></strong></p><div><img img_height=\"446\" img_width=\"640\" inline=\"0\" src=\"https://static.tigerbbs.com/cb885e7eaa274609b4bf510bba5f8c45\"/></div><p><em>（注明：药品红字部分指恒瑞医药已上市的7款创新药，恒瑞医药目前共有10款创新药。）</em></p><p><strong><span>二、恒瑞医药2022年业绩增长有何支撑？</span></strong></p><p><strong><span>因为细细追究来看，我们会发现，事情并没有那么悲观，</span></strong>对于恒瑞医药来说，这是一个不断进化的过程，且净利率端还有当前较大的研发压力，恒瑞医药厚积薄发还是有希望的。</p><p><strong><span>1、仿制药集采虽会扩容，但“新药”上市速度在加快</span></strong></p><p>虽然2021年上半年第三次集采的六款仿制药收入下降了57%，但整体来看，恒瑞医药的收入仍然是在增长的，<strong><span>这一方面和我们一直说道的创新药上市密切相关，另一方面是因为“新的”仿制药也在不断上市。</span></strong></p><p>即2021年上半年恒瑞医药共有<strong><span>14款</span></strong>药品获得药（产）品注册批件，其中有近三分之二都是仿制药；相对应的2020年全年，恒瑞医药取得创新药制剂生产批件为<strong><span>6个</span></strong>、仿制药制剂生产批件也仅有<strong><span>5个</span></strong>，<strong><span>创新药和仿制药上市速度都在加快。</span></strong></p><p>同时，由2022年新一年的集采计划目标，按品种数量来看，2022年将实施的两次集采的规模或不会小于前五次。</p><p><strong><span>所以对于恒瑞医药来说，虽然已知集采会不断深化，但恒瑞医药有能力维持着仿制药的收入规模不会出现突然大幅度的下滑。实现业绩平滑是恒瑞医药尽快转型的一个重要方式。</span></strong></p><div><img img_height=\"266\" img_width=\"640\" inline=\"0\" src=\"https://static.tigerbbs.com/b60b164dcbec4dc0a1605db34816886c\"/></div><p><strong><span>2、创新药拐点可能要早于业绩拐点</span></strong></p><p>恒瑞医药目前的创新药销售情况就好比狗熊掰棒子，刚上市一个产品可能不到半年就加入医保谈判降价了，<strong><span>但追究下去的话我们会发现要不是前前后后这些创新药撑着局面，恒瑞医药怎么可能维持着业绩的稳定。</span></strong></p><p>2021年上半年恒瑞医药创新药收入占比为39.15%，收入规模同比增长了43.8%，而这半年创新药新上市产品有1种，2020年新加入医保的为1种，一共有8款创新药；</p><p>2021年下半年，恒瑞医药又新上市了两款创新药，同时在医保内的创新药数量增加了3种（均为谈判），一共有10款创新药，因此从“结构”和规模上看都没有太大问题。</p><p><strong><span>值得一提的是，恒瑞医药新上市的两款创新药，达尔西利、恒格列净分别是首个国产CDK4/6抑制剂、首个国产SGLT-2抑制剂，二者研发投入累计超过了6.37亿元，相当于PD-1 40%的研发规模，不容小觑。</span></strong></p><p>因此，对于恒瑞医药来说，当前研发进程仍在持续加快，作为净利润端的一大影响因素，研发费用率的提升甚至比销售费用率的提升以及毛利率的下降幅度还要大，<strong><span>但没有前者的投入，又怎么能带来销售费用率和毛利率的正向改善，这是一个一比二的关系。</span></strong></p><p><strong><span>三、总结一下</span></strong></p><p><strong><span>总的来看，我们对于恒瑞医药的看法始终没有改变，</span></strong>虽然前期因为企业参与集采以及医保降价，基本面发生了一些变化，但股价下挫最主要的原因还在于前期预期太高了，如果之前股价没有透支未来好几年的情况或许股价下跌幅度会小点。</p><p>展望未来，恒瑞医药见到希望的曙光可能不需要太久，既然2021年不行，那我们就等2022年，如果再出现价格更低的情况反而也是好的，但在抄底之前，我们要做好充分的准备！（比如说现金流折现算一下乐观或悲观情况下，恒瑞医药的价值。）</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/769dc8865e0dc507ddea5079c2429001","relate_stocks":{"600276":"恒瑞医药"},"source_url":"https://m.toutiao.com/i7054466291519717921/info/?i=7054466291519717921","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204086873","content_text":"巴菲特曾经说过对于质优股永远不卖，他曾说，如果你给我1000亿美元用以交换可口可乐这种饮料在世界上的领先权，我会把钱还给你，并对你说‘这可不成’。但巴菲特也会说，当人们忘记“二加二等于四”这种最基本的常识时，就该是脱手离场的时候了，伯克希尔的保险子公司也曾通过套利获得了异常巨大的利润。如果将巴菲特的投资原则提炼一下的话，那就是对于有高的竞争壁垒（或者说特许经营权）的企业不会卖出，但也会买卖市场上的价格与价值出现偏离的股票。那这时候我就想到了恒瑞医药，它是属于巴菲特认为的哪一类呢，而显然，在我看来，它一定是属于有高竞争壁垒的前者。我想，投资恒瑞医药的人应该都是这么认为的，只是可能没有投资在好的价格上。话不多说，好久没跟踪恒瑞医药了，我们来看看它现在怎么样了。一、业绩增速放缓仍然刺激着股价短期走势根据业绩预增披露原则，近期已有不少企业陆陆续续披露了业绩预增报告，但对于恒瑞医药来说，今年的业绩预增报告肯定是没戏了（净利润同比增长50%或下降50%以上）。2022年1月13日，随着恒瑞医药在投资互动平台中回复2021年前三季度企业业绩增速放缓原因，恒瑞医药便又迎来了接连几日的下跌，昨日甚至进入到了沪股通成交榜，被净卖出了7252.92万元。许久不见，大家还是那么情绪化。但显然，这些都不能证明恒瑞医药短期的基本面又发生了大的变动，只能说股价因为资金流入上涨、流出下跌是很正常的事情。而且早在2021年，恒瑞医药二季度、三季度业绩便呈现出明显下滑趋势，但它的前十大流通股股东，除了香港中央结算有限公司减持了6.9%之外，其他机构均处于不变甚至增持趋势。对于恒瑞医药来说，近两年医保谈判以及仿制药集采都因药品单价的大幅下跌而给企业业绩带来不小压力。大产品PD-1于2020年年末加入医保降幅近85%，紧接着在2021年年末又有四款药，其中包括三款创新药，首次纳入了国家医保目录；除此之外，恒瑞医药一共参与了四次仿制药全国集采，第二次～第五次集采一次都没落下，而且按集采相关规定来看，药品集采对业绩影响一般会在半年后兑现，相关药品收入免不了下降50%。所以衡量来看，在2021年恒瑞医药业绩没有明显起色的背景下，考虑2021的集采和谈判，我们似乎认为恒瑞医药2022业绩增长仍有着不小压力。但如果仅仅是这么考虑，我们可能和那些情绪化的投资者没什么区别，而且有点想当然。（注明：药品红字部分指恒瑞医药已上市的7款创新药，恒瑞医药目前共有10款创新药。）二、恒瑞医药2022年业绩增长有何支撑？因为细细追究来看，我们会发现，事情并没有那么悲观，对于恒瑞医药来说，这是一个不断进化的过程，且净利率端还有当前较大的研发压力，恒瑞医药厚积薄发还是有希望的。1、仿制药集采虽会扩容，但“新药”上市速度在加快虽然2021年上半年第三次集采的六款仿制药收入下降了57%，但整体来看，恒瑞医药的收入仍然是在增长的，这一方面和我们一直说道的创新药上市密切相关，另一方面是因为“新的”仿制药也在不断上市。即2021年上半年恒瑞医药共有14款药品获得药（产）品注册批件，其中有近三分之二都是仿制药；相对应的2020年全年，恒瑞医药取得创新药制剂生产批件为6个、仿制药制剂生产批件也仅有5个，创新药和仿制药上市速度都在加快。同时，由2022年新一年的集采计划目标，按品种数量来看，2022年将实施的两次集采的规模或不会小于前五次。所以对于恒瑞医药来说，虽然已知集采会不断深化，但恒瑞医药有能力维持着仿制药的收入规模不会出现突然大幅度的下滑。实现业绩平滑是恒瑞医药尽快转型的一个重要方式。2、创新药拐点可能要早于业绩拐点恒瑞医药目前的创新药销售情况就好比狗熊掰棒子，刚上市一个产品可能不到半年就加入医保谈判降价了，但追究下去的话我们会发现要不是前前后后这些创新药撑着局面，恒瑞医药怎么可能维持着业绩的稳定。2021年上半年恒瑞医药创新药收入占比为39.15%，收入规模同比增长了43.8%，而这半年创新药新上市产品有1种，2020年新加入医保的为1种，一共有8款创新药；2021年下半年，恒瑞医药又新上市了两款创新药，同时在医保内的创新药数量增加了3种（均为谈判），一共有10款创新药，因此从“结构”和规模上看都没有太大问题。值得一提的是，恒瑞医药新上市的两款创新药，达尔西利、恒格列净分别是首个国产CDK4/6抑制剂、首个国产SGLT-2抑制剂，二者研发投入累计超过了6.37亿元，相当于PD-1 40%的研发规模，不容小觑。因此，对于恒瑞医药来说，当前研发进程仍在持续加快，作为净利润端的一大影响因素，研发费用率的提升甚至比销售费用率的提升以及毛利率的下降幅度还要大，但没有前者的投入，又怎么能带来销售费用率和毛利率的正向改善，这是一个一比二的关系。三、总结一下总的来看，我们对于恒瑞医药的看法始终没有改变，虽然前期因为企业参与集采以及医保降价，基本面发生了一些变化，但股价下挫最主要的原因还在于前期预期太高了，如果之前股价没有透支未来好几年的情况或许股价下跌幅度会小点。展望未来，恒瑞医药见到希望的曙光可能不需要太久，既然2021年不行，那我们就等2022年，如果再出现价格更低的情况反而也是好的，但在抄底之前，我们要做好充分的准备！（比如说现金流折现算一下乐观或悲观情况下，恒瑞医药的价值。）","news_type":1},"isVote":1,"tweetType":1,"viewCount":1025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697110595,"gmtCreate":1642348891810,"gmtModify":1642348892072,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697110595","repostId":"2203742646","repostType":4,"isVote":1,"tweetType":1,"viewCount":1300,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697134510,"gmtCreate":1642348361145,"gmtModify":1642348361455,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Hengrui, steady, hope that more good news will come your way!!","listText":"Hengrui, steady, hope that more good news will come your way!!","text":"Hengrui, steady, hope that more good news will come your way!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697134510","repostId":"2193124115","repostType":2,"repost":{"id":"2193124115","kind":"highlight","pubTimestamp":1640332370,"share":"https://www.laohu8.com/m/news/2193124115?lang=&edition=full","pubTime":"2021-12-24 15:52","market":"hk","language":"zh","title":"恒瑞医药(600276.SH)子公司SHR-1314注射液获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2193124115","media":"智通财经网","summary":"恒瑞医药(600276.SH)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司...","content":"<html><body><div> <p>智通财经APP讯，<a href=\"https://laohu8.com/S/600276\">恒瑞医药</a>(600276.SH)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局(简称“国家药监局”)核准签发关于SHR-1314注射液的《药物临床试验批准通知书》，将于近期开展临床试验。</p><p>据悉，SHR-1314注射液是公司自主研发的一种靶向人IL-17A的重组人源化单克隆抗体，拟用于治疗与IL-17通路相关的自身免疫疾病。</p> </div></body></html>","source":"highlight_zhitongcaijin","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药(600276.SH)子公司SHR-1314注射液获药物临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药(600276.SH)子公司SHR-1314注射液获药物临床试验批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 15:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/628596.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局(简称“国家药监局”)核准签发关于SHR-1314注射液的《药物临床试验批准通知书》，将于近期开展临床试验。据悉，SHR-1314注射液是公司自主研发的一种靶向人IL-17A的重组人源化单克隆抗体，拟用于治疗与IL-17通路相关的自身免疫疾病。</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/628596.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://img.zhitongcaijing.com/astock/11.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","relate_stocks":{"600276":"恒瑞医药","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","BK1583":"高瓴概念","03347":"泰格医药"},"source_url":"http://www.zhitongcaijing.com/content/detail/628596.html","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2193124115","content_text":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局(简称“国家药监局”)核准签发关于SHR-1314注射液的《药物临床试验批准通知书》，将于近期开展临床试验。据悉，SHR-1314注射液是公司自主研发的一种靶向人IL-17A的重组人源化单克隆抗体，拟用于治疗与IL-17通路相关的自身免疫疾病。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697134127,"gmtCreate":1642348302998,"gmtModify":1642348303297,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Congrats for the good news!","listText":"Congrats for the good news!","text":"Congrats for the good news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697134127","repostId":"2202204789","repostType":2,"repost":{"id":"2202204789","kind":"news","pubTimestamp":1641890451,"share":"https://www.laohu8.com/m/news/2202204789?lang=&edition=full","pubTime":"2022-01-11 16:40","market":"sh","language":"zh","title":"恒瑞医药(600276.SH)：恒曲获批开展治疗恶性肿瘤化疗所致血小板减少症Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2202204789","media":"智通财经","summary":"智通财经APP讯，恒瑞医药(600276.SH)公告，近日，公司收到美国食品药品监督管理局(“美国FDA”)关于同意海曲泊帕乙醇胺片进行临床试验的函，将于近期开展Ⅲ期临床试验。试验通俗题目：海曲泊帕治疗恶性肿瘤化疗所致血小板减少症的Ⅲ期临床研究试验。据悉，海曲泊帕乙醇胺片(商品名：恒曲)于2021年6月获得国家药品监督管理局批准用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者的治疗，以及用于对免疫抑制治疗疗效不佳的重型再生障碍性贫血成人患者的治疗。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600276\">恒瑞医药</a>(600276.SH)公告，近日，公司收到美国食品药品监督管理局(“美国FDA”)关于同意海曲泊帕乙醇胺片进行临床试验的函，将于近期开展Ⅲ期临床试验。试验通俗题目：海曲泊帕治疗恶性肿瘤化疗所致血小板减少症的Ⅲ期临床研究试验。</p><p>据悉，海曲泊帕乙醇胺片(商品名：恒曲)于2021年6月获得国家药品监督管理局批准用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者的治疗，以及用于对免疫抑制治疗疗效不佳的重型再生障碍性贫血成人患者的治疗。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药(600276.SH)：恒曲获批开展治疗恶性肿瘤化疗所致血小板减少症Ⅲ期临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药(600276.SH)：恒曲获批开展治疗恶性肿瘤化疗所致血小板减少症Ⅲ期临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-11 16:40 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/638846.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，恒瑞医药(600276.SH)公告，近日，公司收到美国食品药品监督管理局(“美国FDA”)关于同意海曲泊帕乙醇胺片进行临床试验的函，将于近期开展Ⅲ期临床试验。试验通俗题目：海曲泊帕治疗恶性肿瘤化疗所致血小板减少症的Ⅲ期临床研究试验。据悉，海曲泊帕乙醇胺片(商品名：恒曲)于2021年6月获得国家药品监督管理局批准用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/638846.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","relate_stocks":{"600276":"恒瑞医药","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK1583":"高瓴概念","03347":"泰格医药"},"source_url":"http://www.zhitongcaijing.com/content/detail/638846.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2202204789","content_text":"智通财经APP讯，恒瑞医药(600276.SH)公告，近日，公司收到美国食品药品监督管理局(“美国FDA”)关于同意海曲泊帕乙醇胺片进行临床试验的函，将于近期开展Ⅲ期临床试验。试验通俗题目：海曲泊帕治疗恶性肿瘤化疗所致血小板减少症的Ⅲ期临床研究试验。据悉，海曲泊帕乙醇胺片(商品名：恒曲)于2021年6月获得国家药品监督管理局批准用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者的治疗，以及用于对免疫抑制治疗疗效不佳的重型再生障碍性贫血成人患者的治疗。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1611,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697134338,"gmtCreate":1642348247088,"gmtModify":1642348247400,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Interesting...&nbsp;","listText":"Interesting...&nbsp;","text":"Interesting...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697134338","repostId":"2203765768","repostType":2,"repost":{"id":"2203765768","kind":"highlight","pubTimestamp":1642066381,"share":"https://www.laohu8.com/m/news/2203765768?lang=&edition=full","pubTime":"2022-01-13 17:33","market":"us","language":"zh","title":"【北向资金大单买入报告】恒瑞医药获净卖出7.77亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2203765768","media":"金十数据","summary":"1月13日，北向资金全天大幅净卖出5.86亿元。","content":"<html><body><p>1月13日，北向资金全天大幅<strong>净</strong><strong>卖出5.86亿元</strong>。其中沪股通<strong>净买入14.54亿元</strong>，深股通<strong>净卖出20.4亿元</strong>。</p>\n<p><img src=\"https://flash-scdn.jin10.com/flash_dli/img/7af323c3-f700-4346-bb21-ed290c04a8d1.jpg\"/></p>\n<p>今日，<strong><a href=\"https://laohu8.com/S/600519\">贵州茅台</a></strong>、<strong><a href=\"https://laohu8.com/S/600276\">恒瑞医药</a></strong>等个股上榜沪股通十大成交活跃股。其中<strong><a href=\"https://laohu8.com/S/600406\">国电南瑞</a></strong>、<strong><a href=\"https://laohu8.com/S/WX\">药明康德</a></strong>、<strong><a href=\"https://laohu8.com/S/601012\">隆基股份</a></strong>、<strong><a href=\"https://laohu8.com/S/600036\">招商银行</a></strong>、<strong><a href=\"https://laohu8.com/S/601318\">中国平安</a></strong>、<strong><a href=\"https://laohu8.com/S/601899\">紫金矿业</a></strong>、<strong><a href=\"https://laohu8.com/S/603799\">华友钴业</a></strong>、<strong>贵州茅台</strong>分别被净买入5.83亿元、3.81亿元、3.67亿元、2.89亿元、2.71亿元、2亿元、1.3亿元、0.76亿元；<strong>恒瑞医药</strong>、<strong>中国巨石</strong>分别被净卖出7.77亿元、5亿元。</p>\n<p><img src=\"https://flash-scdn.jin10.com/flash_dli/img/9143a974-adef-4255-bf81-959f0851c21c.jpg\"/></p>\n<p>深市方面，<strong><a href=\"https://laohu8.com/S/300750\">宁德时代</a></strong>、<strong><a href=\"https://laohu8.com/S/002594\">比亚迪</a></strong>等个股今日上榜深股通十大成交活跃股，其中<strong><a href=\"https://laohu8.com/S/002812\">恩捷股份</a></strong>、<strong><a href=\"https://laohu8.com/S/300014\">亿纬锂能</a></strong>、<strong><a href=\"https://laohu8.com/S/002460\">赣锋锂业</a></strong>分别被净买入3.73亿元、2.71亿元、2.49亿元；<strong><a href=\"https://laohu8.com/S/300015\">爱尔眼科</a></strong>、<strong>比亚迪</strong>、<strong><a href=\"https://laohu8.com/S/000858\">五粮液</a></strong>、<strong>宁德时代</strong>、<strong>东方财富</strong>、<strong><a href=\"https://laohu8.com/S/002475\">立讯精密</a></strong>、<strong><a href=\"https://laohu8.com/S/300760\">迈瑞医疗</a></strong>分别被净卖出5.65亿元、2.86亿元、2.26亿元、2.19亿元、0.48亿元、0.32亿元、0.28亿元。</p>\n<p><img src=\"https://flash-scdn.jin10.com/flash_dli/img/e15a5c34-008a-47c0-9387-512b8391cfa3.jpg\"/></p></body></html>","source":"xnew_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【北向资金大单买入报告】恒瑞医药获净卖出7.77亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【北向资金大单买入报告】恒瑞医药获净卖出7.77亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-13 17:33 北京时间&nbsp;&nbsp;&nbsp;<a href=https://xnews.jin10.com/webapp/details.html?id=88822&type=news><strong>金十数据</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1月13日，北向资金全天大幅净卖出5.86亿元。其中沪股通净买入14.54亿元，深股通净卖出20.4亿元。\n\n今日，贵州茅台、恒瑞医药等个股上榜沪股通十大成交活跃股。其中国电南瑞、药明康德、隆基股份、招商银行、中国平安、紫金矿业、华友钴业、贵州茅台分别被净买入5.83亿元、3.81亿元、3.67亿元、2.89亿元、2.71亿元、2亿元、1.3亿元、0.76亿元；恒瑞医药、中国巨石分别被净卖出...</p>\n\n<a href=\"https://xnews.jin10.com/webapp/details.html?id=88822&type=news\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://cdn.jin10.com/assets/img/long_pic/cover3.jpg/lite","relate_stocks":{"600276":"恒瑞医药"},"source_url":"https://xnews.jin10.com/webapp/details.html?id=88822&type=news","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203765768","content_text":"1月13日，北向资金全天大幅净卖出5.86亿元。其中沪股通净买入14.54亿元，深股通净卖出20.4亿元。\n\n今日，贵州茅台、恒瑞医药等个股上榜沪股通十大成交活跃股。其中国电南瑞、药明康德、隆基股份、招商银行、中国平安、紫金矿业、华友钴业、贵州茅台分别被净买入5.83亿元、3.81亿元、3.67亿元、2.89亿元、2.71亿元、2亿元、1.3亿元、0.76亿元；恒瑞医药、中国巨石分别被净卖出7.77亿元、5亿元。\n\n深市方面，宁德时代、比亚迪等个股今日上榜深股通十大成交活跃股，其中恩捷股份、亿纬锂能、赣锋锂业分别被净买入3.73亿元、2.71亿元、2.49亿元；爱尔眼科、比亚迪、五粮液、宁德时代、东方财富、立讯精密、迈瑞医疗分别被净卖出5.65亿元、2.86亿元、2.26亿元、2.19亿元、0.48亿元、0.32亿元、0.28亿元。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1689,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697135734,"gmtCreate":1642348107918,"gmtModify":1642348108221,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Wow...","listText":"Wow...","text":"Wow...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697135734","repostId":"2203564766","repostType":2,"repost":{"id":"2203564766","kind":"news","pubTimestamp":1642068120,"share":"https://www.laohu8.com/m/news/2203564766?lang=&edition=full","pubTime":"2022-01-13 18:02","market":"hk","language":"zh","title":"北水连续第8日加仓美团，今日再大幅买入超8亿港元；南水抛售恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2203564766","media":"富途牛牛","summary":"南向资金今日净买入13.39亿港元，连续7日净买入。融创中国、美团-W、快手-W分别获净买入8.62亿港元、8.21亿港元、3.4亿港元。香港交易所净卖出额居首，金额为5.79亿港元。南下资金已连续8日净买入美团，累计买入约41.655亿港元。北向资金今日小幅净卖出5.85亿元，恒瑞医药、爱尔眼科、中国巨石分别遭净卖出7.77亿元、5.65亿元、5亿元。净买入方面，国电南瑞、药明康德、恩捷股份净买入额位列前三，分别获净买入5.83亿元、3.81亿元、3.73亿元。编辑/irisz","content":"<html><body><article><p>南向资金今日净买入13.39亿港元，连续7日净买入。<a href=\"https://laohu8.com/S/01918\">融创中国</a>、<a href=\"https://laohu8.com/S/03690\">美团-W</a>、<a href=\"https://laohu8.com/S/01024\">快手-W</a>分别获净买入8.62亿港元、8.21亿港元、3.4亿港元。<a href=\"https://laohu8.com/S/00388\">香港交易所</a>净卖出额居首，金额为5.79亿港元。</p><p>南下资金已连续8日净买入美团，累计买入约41.655亿港元。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20220113180313571v154ec5y7bejsb4\"/><p>北向资金今日小幅净卖出5.85亿元，<a href=\"https://laohu8.com/S/600276\">恒瑞医药</a>、<a href=\"https://laohu8.com/S/300015\">爱尔眼科</a>、<a href=\"https://laohu8.com/S/600176\">中国巨石</a>分别遭净卖出7.77亿元、5.65亿元、5亿元。净买入方面，国电南瑞、<a href=\"https://laohu8.com/S/WX\">药明康德</a>、<a href=\"https://laohu8.com/S/002812\">恩捷股份</a>净买入额位列前三，分别获净买入5.83亿元、3.81亿元、3.73亿元。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20220113180326335v154zowqxjxkmx7\"/><p>编辑/irisz</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>北水连续第8日加仓美团，今日再大幅买入超8亿港元；南水抛售恒瑞医药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n北水连续第8日加仓美团，今日再大幅买入超8亿港元；南水抛售恒瑞医药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-13 18:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202201131803277c6a8b02&s=b><strong>富途牛牛</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>南向资金今日净买入13.39亿港元，连续7日净买入。融创中国、美团-W、快手-W分别获净买入8.62亿港元、8.21亿港元、3.4亿港元。香港交易所净卖出额居首，金额为5.79亿港元。南下资金已连续8日净买入美团，累计买入约41.655亿港元。北向资金今日小幅净卖出5.85亿元，恒瑞医药、爱尔眼科、中国巨石分别遭净卖出7.77亿元、5.65亿元、5亿元。净买入方面，国电南瑞、药明康德、恩捷股份净...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202201131803277c6a8b02&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/76824cd4c5b97eaacdaab63d96995a28","relate_stocks":{"600276":"恒瑞医药","BK1521":"挪威政府全球养老基金持仓","BK1583":"高瓴概念","03690":"美团-W","BK1604":"节假日概念","BK1575":"同股不同权","BK1142":"互联网与直销零售","BK1591":"就地过年概念","BK1589":"北水核心资产"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202201131803277c6a8b02&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2203564766","content_text":"南向资金今日净买入13.39亿港元，连续7日净买入。融创中国、美团-W、快手-W分别获净买入8.62亿港元、8.21亿港元、3.4亿港元。香港交易所净卖出额居首，金额为5.79亿港元。南下资金已连续8日净买入美团，累计买入约41.655亿港元。北向资金今日小幅净卖出5.85亿元，恒瑞医药、爱尔眼科、中国巨石分别遭净卖出7.77亿元、5.65亿元、5亿元。净买入方面，国电南瑞、药明康德、恩捷股份净买入额位列前三，分别获净买入5.83亿元、3.81亿元、3.73亿元。编辑/irisz","news_type":1},"isVote":1,"tweetType":1,"viewCount":1455,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697135585,"gmtCreate":1642347979897,"gmtModify":1642347980167,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Good news!!!","listText":"Good news!!!","text":"Good news!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697135585","repostId":"2203713101","repostType":2,"repost":{"id":"2203713101","kind":"news","pubTimestamp":1642148192,"share":"https://www.laohu8.com/m/news/2203713101?lang=&edition=full","pubTime":"2022-01-14 16:16","market":"sh","language":"zh","title":"恒瑞医药(600276.SH)SHR8008胶囊的药品上市许可申请获药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2203713101","media":"智通财经","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，公司收到国家药品监督管理局(以下简称“药监局”)下发的《受理通知书》，公司提交的SHR8008胶囊的药品上市许可申请获药监局受理。SHR8008是一种新型口服唑类抗真菌药物，可高度特异性抑制真菌CYP51酶，在国外已经完成1项针对急性外阴阴道假丝酵母菌病的临床Ⅱ期研究、1项针对复发性外阴阴道假丝酵母菌病的临床Ⅱ期研究和3项针对复发性外阴阴道假丝酵母菌病的临床Ⅲ期研究。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600276\">恒瑞医药</a>(600276.SH)发布公告，公司收到国家药品监督管理局(以下简称“药监局”)下发的《受理通知书》，公司提交的SHR8008胶囊的药品上市许可申请获药监局受理。</p><p>SHR8008是一种新型口服唑类抗真菌药物，可高度特异性抑制真菌CYP51酶，在国外已经完成1项针对急性外阴阴道假丝酵母菌病的临床Ⅱ期研究、1项针对复发性外阴阴道假丝酵母菌病的临床Ⅱ期研究和3项针对复发性外阴阴道假丝酵母菌病的临床Ⅲ期研究。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药(600276.SH)SHR8008胶囊的药品上市许可申请获药监局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药(600276.SH)SHR8008胶囊的药品上市许可申请获药监局受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-14 16:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/640992.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，恒瑞医药(600276.SH)发布公告，公司收到国家药品监督管理局(以下简称“药监局”)下发的《受理通知书》，公司提交的SHR8008胶囊的药品上市许可申请获药监局受理。SHR8008是一种新型口服唑类抗真菌药物，可高度特异性抑制真菌CYP51酶，在国外已经完成1项针对急性外阴阴道假丝酵母菌病的临床Ⅱ期研究、1项针对复发性外阴阴道假丝酵母菌病的临床Ⅱ期研究和3项针对复发性外阴阴道...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/640992.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{},"source_url":"http://www.zhitongcaijing.com/content/detail/640992.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203713101","content_text":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，公司收到国家药品监督管理局(以下简称“药监局”)下发的《受理通知书》，公司提交的SHR8008胶囊的药品上市许可申请获药监局受理。SHR8008是一种新型口服唑类抗真菌药物，可高度特异性抑制真菌CYP51酶，在国外已经完成1项针对急性外阴阴道假丝酵母菌病的临床Ⅱ期研究、1项针对复发性外阴阴道假丝酵母菌病的临床Ⅱ期研究和3项针对复发性外阴阴道假丝酵母菌病的临床Ⅲ期研究。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600282060,"gmtCreate":1638157965152,"gmtModify":1638157965276,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600282060","repostId":"1124072014","repostType":4,"repost":{"id":"1124072014","kind":"news","pubTimestamp":1638140765,"share":"https://www.laohu8.com/m/news/1124072014?lang=&edition=full","pubTime":"2021-11-29 07:06","market":"us","language":"en","title":"November jobs report: What to know this week","url":"https://stock-news.laohu8.com/highlight/detail?id=1124072014","media":"yahoo","summary":"As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor","content":"<p>As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor market.</p>\n<p>The Labor Department's monthly jobs report due for release on Friday is set to provide an updated snapshot of the strength in hiring and labor force participation in the U.S. economy. Consensus economists are looking for a half-million jobs to have returned in November, with the pace of hiring slowing only slightly from October's 531,000 gain. The unemployment rate is also expected to improve further to 4.5% from October's 4.6%, reaching the lowest level since March 2020.</p>\n<p>\"We expect non-farm payrolls to have risen by 500,000 in November, but the growing risk of a winter COVID wave and a dwindling supply of available workers will weigh on jobs growth soon,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note last week.</p>\n<p>\"Employment growth can’t continue at this pace for much longer unless the labor force stages a more notable recovery. If anything, labor supply could<i>worsen</i>over the coming months as the federal vaccine mandate covering 100 [million] workers begins on January 4,\" Ashworth added. \"That suggests wage growth will remain strong, and we expect a 0.4% [month-over-month] rise in average hourly earnings in October.\"</p>\n<p>On a year-over-year basis, average hourly earnings are expected to rise by 5.0%, accelerating even further after October's already marked 4.9% rise and representing the fastest wage growth rate since February.</p>\n<p>Growing average wages and a tight labor market — while a positive for consumers and their ability to spend — has also stoked concerns over persistent inflation. Last week's Personal Consumption Expenditures (PCE) deflator from the Bureau of Economic Analysis for October showed an annual jump of 5.0% in the index, or the biggest rise since 1990. And the core PCE, or the Fed's preferred inflation gauge stripping out volatile food and energy prices, rose by 4.1% year-over-year — the most in three decades.</p>\n<p>Other recent data have homed in on the tight labor market and presaged a potentially strong November jobs report. Last week'sinitial jobless claims fell to a 52-year low of 199,000, taking out both the prior pandemic-era low and pre-pandemic average for new first-time filings. This served as yet another point underscoring the steep competition for labor among U.S. employers, with companies attempting to hire and retain their existing workforces amid widespread labor shortages.</p>\n<p>Even given these lingering scarcities, the labor force participation rate has yet to return to pre-pandemic levels. The civilian labor force was still down by nearly 3 million participants compared to February 2020, with lingering concerns over the virus and adesire by many working-age individuals to seek out new roles with better flexibility and benefitsstill keeping many individuals on the sidelines of the workforce. Consensus economists expect the labor force participation rate to tick up only slightly in November to reach 61.7%, growing from October's 61.6% but coming in well below the 63.3% rate from February 2020.</p>\n<p>Returning the economy back to pre-pandemic labor force participation levels and ensuring job gains are seen equitably across different groups has become a key focus for the Federal Reserve. And the distance still left to make up on these fronts has also been the biggest factor keeping the Fed ultra-accommodative with its monetary policy support, even after a parade of hotter-than-expected inflation reports that would appear to warrant a more hawkish policy tilt and a quicker-than-expected hike to interest rates.Fed Chair Jerome Powell's renomination to remain as head of the central bankfurther suggests the Fed's focus on the labor market as a critical informing factor for monetary policy will remain.</p>\n<p>\"Market views for future Fed rate increases have been pulled forward aggressively in response to evidence that elevated inflation pressures are likely to persist for longer,\" wrote Deutsche Bank economist Justin Weidner in a note last week. \"However, as Chair Powell's November press conference made evident, prospects for the labor market to return to maximum employment remain a critical consideration for when the Fed will eventually begin to actively tighten monetary policy.\"</p>\n<p>Economic calendar</p>\n<ul>\n <li><p><b>Monday:</b>Pending home sales, month-over-month, October (0.7% expected, -2.3% in September); Dallas Federal Reserve Manufacturing Activity Index, November (17.0 expected, 14.6 in October)</p></li>\n <li><p><b>Tuesday:</b>FHFA House Price Index, month-over-month, September (1.2% expected, 1.0% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, September (1.30% expected, 1.17% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, September (19.66% during prior month); MNI Chicago PMI, November (67.0 expected, 68.4 in October); Conference Board Consumer Confidence Index, November (110.0 expected, 113.8 in October)</p></li>\n <li><p><b>Wednesday:</b>MBA Mortgage Applications, November 26 (1.8% during prior week); ADP Employment Change, November (515,000 expected, 571,000 in October); Markit U.S. Manufacturing PMI, November final (59.1 during prior month); Construction Spending, month-over-month, October (0.5% expected, -0.5% in September); ISM Manufacturing, November (61.0 expected, 60.8 in October); Federal Reserve releases Beige Book</p></li>\n <li><p><b>Thursday:</b>Challenger job cuts, November (-71.7% in October); Initial jobless claims, week ended Nov. 27 (199,000 during prior week); Continuing claims, Nov. 20 (2.049 during prior week)</p></li>\n <li><p><b>Friday:</b>Change in non-farm payrolls, November (500,000 expected, 531,000 in October); Unemployment rate, November (4.5% expected, 4.6% in October); Average Hourly Earnings, month-over-month, November (0.4% expected, 0.4% in October); Average Hourly Earnings, year-over-year, November (5.0% expected, 4.9% in October); Markit U.S. Services PMI, November final (57.0 in prior print); Markit U.S. Composite PMI, November final (56.5 in prior print); ISM Services Index, November (65.0 expected, 66.7 in October); Factory Orders, October (0.5% expected, 0.2% in September); Durable Goods Orders, October final (-0.5% in prior print)</p></li>\n</ul>\n<p>Earnings calendar</p>\n<ul>\n <li><p><b>Monday:</b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Tuesday:</b>Salesforce.com (CRM) after market close</p></li>\n <li><p><b>Wednesday:</b>PVH Corp. (PVH) after market close</p></li>\n <li><p><b>Thursday:</b>Dollar General (DG), Kroger (KR) before market open; Ulta Beauty (ULTA) after market close</p></li>\n <li><p><b>Friday:</b><i>No notable reports scheduled for release</i></p></li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>November jobs report: What to know this week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovember jobs report: What to know this week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 07:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/november-jobs-report-what-to-know-this-week-144428419.html><strong>yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor market.\nThe Labor Department's monthly jobs report due for release on Friday is set to provide an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/november-jobs-report-what-to-know-this-week-144428419.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRM":"赛富时"},"source_url":"https://finance.yahoo.com/news/november-jobs-report-what-to-know-this-week-144428419.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124072014","content_text":"As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor market.\nThe Labor Department's monthly jobs report due for release on Friday is set to provide an updated snapshot of the strength in hiring and labor force participation in the U.S. economy. Consensus economists are looking for a half-million jobs to have returned in November, with the pace of hiring slowing only slightly from October's 531,000 gain. The unemployment rate is also expected to improve further to 4.5% from October's 4.6%, reaching the lowest level since March 2020.\n\"We expect non-farm payrolls to have risen by 500,000 in November, but the growing risk of a winter COVID wave and a dwindling supply of available workers will weigh on jobs growth soon,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note last week.\n\"Employment growth can’t continue at this pace for much longer unless the labor force stages a more notable recovery. If anything, labor supply couldworsenover the coming months as the federal vaccine mandate covering 100 [million] workers begins on January 4,\" Ashworth added. \"That suggests wage growth will remain strong, and we expect a 0.4% [month-over-month] rise in average hourly earnings in October.\"\nOn a year-over-year basis, average hourly earnings are expected to rise by 5.0%, accelerating even further after October's already marked 4.9% rise and representing the fastest wage growth rate since February.\nGrowing average wages and a tight labor market — while a positive for consumers and their ability to spend — has also stoked concerns over persistent inflation. Last week's Personal Consumption Expenditures (PCE) deflator from the Bureau of Economic Analysis for October showed an annual jump of 5.0% in the index, or the biggest rise since 1990. And the core PCE, or the Fed's preferred inflation gauge stripping out volatile food and energy prices, rose by 4.1% year-over-year — the most in three decades.\nOther recent data have homed in on the tight labor market and presaged a potentially strong November jobs report. Last week'sinitial jobless claims fell to a 52-year low of 199,000, taking out both the prior pandemic-era low and pre-pandemic average for new first-time filings. This served as yet another point underscoring the steep competition for labor among U.S. employers, with companies attempting to hire and retain their existing workforces amid widespread labor shortages.\nEven given these lingering scarcities, the labor force participation rate has yet to return to pre-pandemic levels. The civilian labor force was still down by nearly 3 million participants compared to February 2020, with lingering concerns over the virus and adesire by many working-age individuals to seek out new roles with better flexibility and benefitsstill keeping many individuals on the sidelines of the workforce. Consensus economists expect the labor force participation rate to tick up only slightly in November to reach 61.7%, growing from October's 61.6% but coming in well below the 63.3% rate from February 2020.\nReturning the economy back to pre-pandemic labor force participation levels and ensuring job gains are seen equitably across different groups has become a key focus for the Federal Reserve. And the distance still left to make up on these fronts has also been the biggest factor keeping the Fed ultra-accommodative with its monetary policy support, even after a parade of hotter-than-expected inflation reports that would appear to warrant a more hawkish policy tilt and a quicker-than-expected hike to interest rates.Fed Chair Jerome Powell's renomination to remain as head of the central bankfurther suggests the Fed's focus on the labor market as a critical informing factor for monetary policy will remain.\n\"Market views for future Fed rate increases have been pulled forward aggressively in response to evidence that elevated inflation pressures are likely to persist for longer,\" wrote Deutsche Bank economist Justin Weidner in a note last week. \"However, as Chair Powell's November press conference made evident, prospects for the labor market to return to maximum employment remain a critical consideration for when the Fed will eventually begin to actively tighten monetary policy.\"\nEconomic calendar\n\nMonday:Pending home sales, month-over-month, October (0.7% expected, -2.3% in September); Dallas Federal Reserve Manufacturing Activity Index, November (17.0 expected, 14.6 in October)\nTuesday:FHFA House Price Index, month-over-month, September (1.2% expected, 1.0% in August); S&P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, September (1.30% expected, 1.17% in August); S&P CoreLogic Case-Shiller 20-City Composite Index, September (19.66% during prior month); MNI Chicago PMI, November (67.0 expected, 68.4 in October); Conference Board Consumer Confidence Index, November (110.0 expected, 113.8 in October)\nWednesday:MBA Mortgage Applications, November 26 (1.8% during prior week); ADP Employment Change, November (515,000 expected, 571,000 in October); Markit U.S. Manufacturing PMI, November final (59.1 during prior month); Construction Spending, month-over-month, October (0.5% expected, -0.5% in September); ISM Manufacturing, November (61.0 expected, 60.8 in October); Federal Reserve releases Beige Book\nThursday:Challenger job cuts, November (-71.7% in October); Initial jobless claims, week ended Nov. 27 (199,000 during prior week); Continuing claims, Nov. 20 (2.049 during prior week)\nFriday:Change in non-farm payrolls, November (500,000 expected, 531,000 in October); Unemployment rate, November (4.5% expected, 4.6% in October); Average Hourly Earnings, month-over-month, November (0.4% expected, 0.4% in October); Average Hourly Earnings, year-over-year, November (5.0% expected, 4.9% in October); Markit U.S. Services PMI, November final (57.0 in prior print); Markit U.S. Composite PMI, November final (56.5 in prior print); ISM Services Index, November (65.0 expected, 66.7 in October); Factory Orders, October (0.5% expected, 0.2% in September); Durable Goods Orders, October final (-0.5% in prior print)\n\nEarnings calendar\n\nMonday:No notable reports scheduled for release\nTuesday:Salesforce.com (CRM) after market close\nWednesday:PVH Corp. (PVH) after market close\nThursday:Dollar General (DG), Kroger (KR) before market open; Ulta Beauty (ULTA) after market close\nFriday:No notable reports scheduled for release","news_type":1},"isVote":1,"tweetType":1,"viewCount":1237,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873524468,"gmtCreate":1636965428451,"gmtModify":1636965428883,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Interesting... Will included in my watchlist&nbsp;","listText":"Interesting... Will included in my watchlist&nbsp;","text":"Interesting... Will included in my watchlist","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873524468","repostId":"2178368602","repostType":2,"isVote":1,"tweetType":1,"viewCount":1772,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870762154,"gmtCreate":1636649014814,"gmtModify":1636649015297,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Good job","listText":"Good job","text":"Good job","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870762154","repostId":"2180682817","repostType":2,"repost":{"id":"2180682817","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1635970475,"share":"https://www.laohu8.com/m/news/2180682817?lang=&edition=full","pubTime":"2021-11-04 04:14","market":"us","language":"en","title":"CRISPR Therapeutics Q3 Sales $300.00K Up From $148.00K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2180682817","media":"Benzinga","summary":"CRISPR Therapeutics (NASDAQ:CRSP) reported $300.00 thousand in sales this quarter. This is a 102.70 percent increase over sales of $148.00 thousand the same period last year.","content":"<html><body><p>CRISPR Therapeutics (NASDAQ:CRSP) reported $300.00 thousand in sales this quarter. This is a 102.70 percent increase over sales of $148.00 thousand the same period last year.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CRISPR Therapeutics Q3 Sales $300.00K Up From $148.00K YoY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCRISPR Therapeutics Q3 Sales $300.00K Up From $148.00K YoY\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-11-04 04:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>CRISPR Therapeutics (NASDAQ:CRSP) reported $300.00 thousand in sales this quarter. This is a 102.70 percent increase over sales of $148.00 thousand the same period last year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRSP":"CRISPR Therapeutics AG"},"source_url":"https://www.benzinga.com/news/earnings/21/11/23872086/crispr-therapeutics-q3-sales-300-00k-up-from-148-00k-yoy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180682817","content_text":"CRISPR Therapeutics (NASDAQ:CRSP) reported $300.00 thousand in sales this quarter. This is a 102.70 percent increase over sales of $148.00 thousand the same period last year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870667736,"gmtCreate":1636613181375,"gmtModify":1636613181532,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Will see how the result goes in next quarter...","listText":"Will see how the result goes in next quarter...","text":"Will see how the result goes in next quarter...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870667736","repostId":"1101863758","repostType":4,"repost":{"id":"1101863758","kind":"news","pubTimestamp":1636610470,"share":"https://www.laohu8.com/m/news/1101863758?lang=&edition=full","pubTime":"2021-11-11 14:01","market":"us","language":"en","title":"Why Palantir Stock Dropped on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1101863758","media":"Motley Fool","summary":"What happened\nShares of Palantir Technologies fell 7% on Wednesday, following bearish analyst commen","content":"<p>What happened</p>\n<p>Shares of Palantir Technologies&nbsp;fell 7% on Wednesday, following bearish analyst commentary.</p>\n<p><img src=\"https://static.tigerbbs.com/13f94be27affe668764a0a9f5a12d01f\" tg-width=\"881\" tg-height=\"642\" width=\"100%\" height=\"auto\">So what</p>\n<p>Palantir's revenue climbed 36% year over year to $392 million in the third quarter. That marked a notable deceleration from the 49% growth the data software provider delivered in the second quarter.</p>\n<p>The slowdown was enough for RBC Capital analyst Rishi Jaluria to cut his rating on Palantir's stock from sector perform to underperform and slash his share price forecast from $25 to $19.</p>\n<p>Jaluria was particularly concerned with the decline in Palantir's revenue growth rate in its core government business, which fell to 34% from 66% in the second quarter. \"We believe Palantir got direct benefits from COVID-related spending and those benefits have already faded,\" Jaluria said.</p>\n<p>Moreover, although Palantir saw its U.S. commercial revenue rise by an impressive 103% in the third quarter, Jaluria argued that this level of growth is unsustainable. He noted that Palantir's commercial business has benefited from its strategy of investing in newly public companies in exchange for them agreeing to use its software. Jaluria believes these investments will have less of an impact over time.</p>\n<p>For these reasons, Jaluria is now less confident that Palantir can achieve its revenue growth target of at least 30% annually through 2025.</p>\n<p>Now what</p>\n<p>As a premium-priced growth stock, Palantir is highly exposed to anything that would make investors question whether it can reach its long-term expansion goals. Even after today's stock price decline, Palantir's shares trade for more than 100 times its projected earnings in 2022. Thus, should more analysts raise concerns about its growth projections, Palantir's share price could have further to fall.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Palantir Stock Dropped on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Palantir Stock Dropped on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-11 14:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/10/why-palantir-stock-dropped-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Palantir Technologies fell 7% on Wednesday, following bearish analyst commentary.\nSo what\nPalantir's revenue climbed 36% year over year to $392 million in the third quarter. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/10/why-palantir-stock-dropped-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://www.fool.com/investing/2021/11/10/why-palantir-stock-dropped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101863758","content_text":"What happened\nShares of Palantir Technologies fell 7% on Wednesday, following bearish analyst commentary.\nSo what\nPalantir's revenue climbed 36% year over year to $392 million in the third quarter. That marked a notable deceleration from the 49% growth the data software provider delivered in the second quarter.\nThe slowdown was enough for RBC Capital analyst Rishi Jaluria to cut his rating on Palantir's stock from sector perform to underperform and slash his share price forecast from $25 to $19.\nJaluria was particularly concerned with the decline in Palantir's revenue growth rate in its core government business, which fell to 34% from 66% in the second quarter. \"We believe Palantir got direct benefits from COVID-related spending and those benefits have already faded,\" Jaluria said.\nMoreover, although Palantir saw its U.S. commercial revenue rise by an impressive 103% in the third quarter, Jaluria argued that this level of growth is unsustainable. He noted that Palantir's commercial business has benefited from its strategy of investing in newly public companies in exchange for them agreeing to use its software. Jaluria believes these investments will have less of an impact over time.\nFor these reasons, Jaluria is now less confident that Palantir can achieve its revenue growth target of at least 30% annually through 2025.\nNow what\nAs a premium-priced growth stock, Palantir is highly exposed to anything that would make investors question whether it can reach its long-term expansion goals. Even after today's stock price decline, Palantir's shares trade for more than 100 times its projected earnings in 2022. Thus, should more analysts raise concerns about its growth projections, Palantir's share price could have further to fall.","news_type":1},"isVote":1,"tweetType":1,"viewCount":511,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845445718,"gmtCreate":1636363763203,"gmtModify":1636364027631,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Steady","listText":"Steady","text":"Steady","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845445718","repostId":"1107472736","repostType":4,"repost":{"id":"1107472736","kind":"news","pubTimestamp":1636357314,"share":"https://www.laohu8.com/m/news/1107472736?lang=&edition=full","pubTime":"2021-11-08 15:41","market":"us","language":"en","title":"Buffett’s Berkshire Appetite Surpasses Cash Spent on Apple Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1107472736","media":"Bloomberg","summary":"(Bloomberg) -- Warren Buffett has spent more money buying back Berkshire Hathaway Inc.’s stock in re","content":"<p>(Bloomberg) -- Warren Buffett has spent more money buying back Berkshire Hathaway Inc.’s stock in recent years than he did amassing his biggest equity bet on Apple Inc.</p>\n<p>Berkshire spent nearly $20 billion more repurchasing its own stock since the middle of 2018 than it deployed accumulating its Apple stake through the end of last year. In total, Buffett poured about $51 billion into buybacks since a change to its policy more than three years ago, and appears to have continued snapping up at least $1.7 billion of stock since the end of September.</p>\n<p>Buffett, Berkshire’s chairman and chief executive officer, has built Berkshire into a sprawling conglomerate valued at more than $650 billion, but that immense size has heaped pressure on his need for what he deemed an “elephant-sized” acquisition to ramp up Berkshire’s growth. Buffett has been foiled on his recent deal hunt, outbid at times by aggressive private equity firms. That’s left him increasingly relying on buybacks, with more than $20 billion of repurchases so far this year, as a way to put some of Berkshire’s record cash pile to work.</p>\n<p>“The bull case would say they bought back $20 billion worth of their stock because they’re confident in their future outlook and that should be a catalyst for the stock, and my sense is it probably will,” Cathy Seifert, an analyst at CFRA Research, said. “The bear case, which is also relevant to point out, is this is a company that has had, as a stated desire, the need to make additional acquisitions and they haven’t been able to do that.”</p>\n<p>It’s a marked shift for a CEO who previously shunned buybacks. For years, Buffett preferred large deals and spending money snapping up other company’s stocks over repurchasing Berkshire’s own shares. But that changed in 2018 when the company’s board lifted a cap on buybacks, giving Buffett and his longtime business partner, Charlie Munger, more flexibility to parcel out profits.</p>\n<p>Buybacks have now surpassed even Berkshire’s largest holding, an Apple Inc. stake valued at more than $121 billion at the end of September. The company has spent just $31 billion buying Apple shares since it began accumulating that stake in 2016 through the end of 2020, according to the most recent data available.</p>\n<p>What Bloomberg Intelligence Says</p>\n<p>“We believe Warren Buffett’s significant share repurchases show his conservatism as rising valuations make deals he may find attractive more scarce.”</p>\n<p>-- Matthew Palazola and Kylie Towbin, BI analysts</p>\n<p>All the buyback activity, while significant in size, hasn’t been enough to meaningfully whittle away some of the conglomerate’s cash. Berkshire ended September with a record $149.2 billion of funds in its coffers. While investors often want management to remain disciplined on when and how it spends the money, the swelling cash pile is “somewhat disappointing,” according to Edward Jones analyst Jim Shanahan.</p>\n<p>“Buybacks were fine, but cash balances increased again,” Shanahan said. “Cash is now approaching $150 billion. That certainly was unexpected earlier this calendar year, I would have thought they would have been able to manage that lower with a combination of investments, acquisitions and buybacks.”</p>\n<p>The Omaha, Nebraska-based business, which reported third-quarter earnings Saturday, posted an 18% gain in operating profit during that period, buoyed by record railroad earnings and strong results from its energy businesses. That helped offset even more underwriting losses at its group of insurers, which have been hit by catastrophes such as Hurricane Ida and more frequent claims from its drivers at auto insurer Geico.</p>\n<p>Berkshire also disclosed that it bought back at least $1.7 billion in stock from the end of September through October 27, according to Saturday’s filing. Empire Financial Research’s Whitney Tilson, who’s attended the Berkshire annual meeting for more than two decades, applauded the buyback, but noted that he’d still prefer to see Buffett find the next lucrative stock bet.</p>\n<p>“If Buffett could find another Apple, clearly I’d rather have him allocate to that,” Tilson said. “Buying back Berkshire stock makes sense when you’re drowning in cash.”</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buffett’s Berkshire Appetite Surpasses Cash Spent on Apple Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuffett’s Berkshire Appetite Surpasses Cash Spent on Apple Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-08 15:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/buffett-berkshire-appetite-surpasses-cash-173252893.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Warren Buffett has spent more money buying back Berkshire Hathaway Inc.’s stock in recent years than he did amassing his biggest equity bet on Apple Inc.\nBerkshire spent nearly $20 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/buffett-berkshire-appetite-surpasses-cash-173252893.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://finance.yahoo.com/news/buffett-berkshire-appetite-surpasses-cash-173252893.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107472736","content_text":"(Bloomberg) -- Warren Buffett has spent more money buying back Berkshire Hathaway Inc.’s stock in recent years than he did amassing his biggest equity bet on Apple Inc.\nBerkshire spent nearly $20 billion more repurchasing its own stock since the middle of 2018 than it deployed accumulating its Apple stake through the end of last year. In total, Buffett poured about $51 billion into buybacks since a change to its policy more than three years ago, and appears to have continued snapping up at least $1.7 billion of stock since the end of September.\nBuffett, Berkshire’s chairman and chief executive officer, has built Berkshire into a sprawling conglomerate valued at more than $650 billion, but that immense size has heaped pressure on his need for what he deemed an “elephant-sized” acquisition to ramp up Berkshire’s growth. Buffett has been foiled on his recent deal hunt, outbid at times by aggressive private equity firms. That’s left him increasingly relying on buybacks, with more than $20 billion of repurchases so far this year, as a way to put some of Berkshire’s record cash pile to work.\n“The bull case would say they bought back $20 billion worth of their stock because they’re confident in their future outlook and that should be a catalyst for the stock, and my sense is it probably will,” Cathy Seifert, an analyst at CFRA Research, said. “The bear case, which is also relevant to point out, is this is a company that has had, as a stated desire, the need to make additional acquisitions and they haven’t been able to do that.”\nIt’s a marked shift for a CEO who previously shunned buybacks. For years, Buffett preferred large deals and spending money snapping up other company’s stocks over repurchasing Berkshire’s own shares. But that changed in 2018 when the company’s board lifted a cap on buybacks, giving Buffett and his longtime business partner, Charlie Munger, more flexibility to parcel out profits.\nBuybacks have now surpassed even Berkshire’s largest holding, an Apple Inc. stake valued at more than $121 billion at the end of September. The company has spent just $31 billion buying Apple shares since it began accumulating that stake in 2016 through the end of 2020, according to the most recent data available.\nWhat Bloomberg Intelligence Says\n“We believe Warren Buffett’s significant share repurchases show his conservatism as rising valuations make deals he may find attractive more scarce.”\n-- Matthew Palazola and Kylie Towbin, BI analysts\nAll the buyback activity, while significant in size, hasn’t been enough to meaningfully whittle away some of the conglomerate’s cash. Berkshire ended September with a record $149.2 billion of funds in its coffers. While investors often want management to remain disciplined on when and how it spends the money, the swelling cash pile is “somewhat disappointing,” according to Edward Jones analyst Jim Shanahan.\n“Buybacks were fine, but cash balances increased again,” Shanahan said. “Cash is now approaching $150 billion. That certainly was unexpected earlier this calendar year, I would have thought they would have been able to manage that lower with a combination of investments, acquisitions and buybacks.”\nThe Omaha, Nebraska-based business, which reported third-quarter earnings Saturday, posted an 18% gain in operating profit during that period, buoyed by record railroad earnings and strong results from its energy businesses. That helped offset even more underwriting losses at its group of insurers, which have been hit by catastrophes such as Hurricane Ida and more frequent claims from its drivers at auto insurer Geico.\nBerkshire also disclosed that it bought back at least $1.7 billion in stock from the end of September through October 27, according to Saturday’s filing. Empire Financial Research’s Whitney Tilson, who’s attended the Berkshire annual meeting for more than two decades, applauded the buyback, but noted that he’d still prefer to see Buffett find the next lucrative stock bet.\n“If Buffett could find another Apple, clearly I’d rather have him allocate to that,” Tilson said. “Buying back Berkshire stock makes sense when you’re drowning in cash.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845170146,"gmtCreate":1636324728235,"gmtModify":1636324728647,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Emmm....","listText":"Emmm....","text":"Emmm....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845170146","repostId":"2180739446","repostType":2,"isVote":1,"tweetType":1,"viewCount":413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840590596,"gmtCreate":1635655465025,"gmtModify":1635655465179,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Alright!","listText":"Alright!","text":"Alright!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840590596","repostId":"1104228860","repostType":4,"isVote":1,"tweetType":1,"viewCount":696,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852531319,"gmtCreate":1635290310555,"gmtModify":1635290313001,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Looking forward","listText":"Looking forward","text":"Looking forward","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852531319","repostId":"2175611011","repostType":2,"isVote":1,"tweetType":1,"viewCount":993,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856560044,"gmtCreate":1635203228838,"gmtModify":1635203229283,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856560044","repostId":"2178467422","repostType":4,"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856582067,"gmtCreate":1635202994894,"gmtModify":1635203006689,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Shall see","listText":"Shall see","text":"Shall see","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856582067","repostId":"2178276504","repostType":4,"isVote":1,"tweetType":1,"viewCount":372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856589039,"gmtCreate":1635202795662,"gmtModify":1635202796059,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Looking forward","listText":"Looking forward","text":"Looking forward","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856589039","repostId":"1163628063","repostType":4,"isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856166008,"gmtCreate":1635161868226,"gmtModify":1635161868657,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Let's go!!!","listText":"Let's go!!!","text":"Let's go!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856166008","repostId":"1158353877","repostType":4,"repost":{"id":"1158353877","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635161224,"share":"https://www.laohu8.com/m/news/1158353877?lang=&edition=full","pubTime":"2021-10-25 19:27","market":"us","language":"en","title":"Tesla shares rose more than 4% in premarket trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1158353877","media":"Tiger Newspress","summary":"Tesla shares rose more than 4% in premarket trading.\nHertz Global Holdings Inc., barely four months ","content":"<p>Tesla&nbsp;shares&nbsp;rose&nbsp;more&nbsp;than&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/7c0ce6b1c030f3cb1213aa47ad4646f3\" tg-width=\"884\" tg-height=\"607\" referrerpolicy=\"no-referrer\">Hertz Global Holdings Inc., barely four months out of bankruptcy, placed an order for 100,000 Teslas in the first step of an ambitious plan to electrify its rental-car fleet, according to people with knowledge of the matter, Bloomberg News reports.</p>\n<p>It’s the single-largest purchase ever for electric vehicles and represents about $4.2 billion of revenue forTesla Inc., according to the people, who asked not to be identified because the information is private.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla shares rose more than 4% in premarket trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla shares rose more than 4% in premarket trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-25 19:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla&nbsp;shares&nbsp;rose&nbsp;more&nbsp;than&nbsp;4%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/7c0ce6b1c030f3cb1213aa47ad4646f3\" tg-width=\"884\" tg-height=\"607\" referrerpolicy=\"no-referrer\">Hertz Global Holdings Inc., barely four months out of bankruptcy, placed an order for 100,000 Teslas in the first step of an ambitious plan to electrify its rental-car fleet, according to people with knowledge of the matter, Bloomberg News reports.</p>\n<p>It’s the single-largest purchase ever for electric vehicles and represents about $4.2 billion of revenue forTesla Inc., according to the people, who asked not to be identified because the information is private.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158353877","content_text":"Tesla shares rose more than 4% in premarket trading.\nHertz Global Holdings Inc., barely four months out of bankruptcy, placed an order for 100,000 Teslas in the first step of an ambitious plan to electrify its rental-car fleet, according to people with knowledge of the matter, Bloomberg News reports.\nIt’s the single-largest purchase ever for electric vehicles and represents about $4.2 billion of revenue forTesla Inc., according to the people, who asked not to be identified because the information is private.","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856161756,"gmtCreate":1635161823019,"gmtModify":1635161823409,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Steady","listText":"Steady","text":"Steady","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/856161756","repostId":"2178808449","repostType":4,"isVote":1,"tweetType":1,"viewCount":309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":898003947,"gmtCreate":1628437909789,"gmtModify":1633747142728,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment&nbsp;","listText":"Please like and comment&nbsp;","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/898003947","repostId":"1180529438","repostType":4,"repost":{"id":"1180529438","kind":"news","pubTimestamp":1628386129,"share":"https://www.laohu8.com/m/news/1180529438?lang=&edition=full","pubTime":"2021-08-08 09:28","market":"us","language":"en","title":"SEC Moves First DeFi Unregistered Securities Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=1180529438","media":"Benzinga","summary":"The United States Securities and Exchange Commission  sued the organization responsible for the development of a decentralized finance  protocol over activities involved with the project for the first time.What Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purported","content":"<p>The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project for the first time.</p>\n<p><b>What Happened:</b>&nbsp;According to a Friday SEC&nbsp;announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purportedly sold over $30 million worth of two types of tokens that the SEC deemed to be securities that should have been registered as such.</p>\n<p>The SEC notes that Blockchain Credit Partners&nbsp;founders Gregory Keough and Derek Acree will have to pay fines of $125,000 while the company itself also agreed to pay $12.8 million in disgorgement. The settlement does not indicate an admition or denial&nbsp;the accusations.</p>\n<p><b>New Game, Old Rules?</b></p>\n<p>SEC Enforcement Director Gurbir Grewal explained that \"full and honest disclosure remains the cornerstone of our securities laws — no matter what technologies are used to offer and sell those securities.\" This comment makes it very clear that slapping the DeFi label on a project and hoping to avoid regulation this way works no better than calling it a \"utility token\" prevented falling under the SEC's scrutiny during 2017's initial coin offering craze.</p>\n<p>The SEC is trying to send the clear rule that the new kind of financial organizations that operate on blockchains have to still play by the old rules that govern traditional finance. At the same time, market onlookers are not sure if the regulator is actually right.</p>\n<p>In a way, it is a tour de force where the regulator wins every time it has a way to take enforcement action, but these new organizations potentially have a very real way to make enforcement impossible — or at the very least impractical. The only protection against enforcement by the SEC and other regulators is decentralization and the only reason why the SEC was able to act in this case is that a centralized organization such as Blockchain Credit Partners exists.</p>\n<p><b>What's Next:</b>If no company exists and all that there is to a DeFi protocol is a set of smart contracts deployed on a blockchain by a group of anonymous developers scattered around the world there is very little that the SEC can do short of attacking the blockchain itself. This is where the decentralization of the underlying blockchain comes into play: will the regulators for instance be able to force&nbsp;<b>Ethereum's</b>&nbsp;(CRYPTO: ETH) core development team to write an update stopping such a project?</p>\n<p>If the regulators would actually be able to force the blockchain's developers to write such an update, would node operators and miners or stakers adopt this software or would they refuse to? Such situations will be the real test of the decentralization and reliability of any blockchain that many are waiting to happen. Regulators are seeing power slipping away&nbsp;between their fingers like sand, and they are going to try to grab it.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SEC Moves First DeFi Unregistered Securities Lawsuit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSEC Moves First DeFi Unregistered Securities Lawsuit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-08 09:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180529438","content_text":"The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project for the first time.\nWhat Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purportedly sold over $30 million worth of two types of tokens that the SEC deemed to be securities that should have been registered as such.\nThe SEC notes that Blockchain Credit Partners founders Gregory Keough and Derek Acree will have to pay fines of $125,000 while the company itself also agreed to pay $12.8 million in disgorgement. The settlement does not indicate an admition or denial the accusations.\nNew Game, Old Rules?\nSEC Enforcement Director Gurbir Grewal explained that \"full and honest disclosure remains the cornerstone of our securities laws — no matter what technologies are used to offer and sell those securities.\" This comment makes it very clear that slapping the DeFi label on a project and hoping to avoid regulation this way works no better than calling it a \"utility token\" prevented falling under the SEC's scrutiny during 2017's initial coin offering craze.\nThe SEC is trying to send the clear rule that the new kind of financial organizations that operate on blockchains have to still play by the old rules that govern traditional finance. At the same time, market onlookers are not sure if the regulator is actually right.\nIn a way, it is a tour de force where the regulator wins every time it has a way to take enforcement action, but these new organizations potentially have a very real way to make enforcement impossible — or at the very least impractical. The only protection against enforcement by the SEC and other regulators is decentralization and the only reason why the SEC was able to act in this case is that a centralized organization such as Blockchain Credit Partners exists.\nWhat's Next:If no company exists and all that there is to a DeFi protocol is a set of smart contracts deployed on a blockchain by a group of anonymous developers scattered around the world there is very little that the SEC can do short of attacking the blockchain itself. This is where the decentralization of the underlying blockchain comes into play: will the regulators for instance be able to force Ethereum's (CRYPTO: ETH) core development team to write an update stopping such a project?\nIf the regulators would actually be able to force the blockchain's developers to write such an update, would node operators and miners or stakers adopt this software or would they refuse to? Such situations will be the real test of the decentralization and reliability of any blockchain that many are waiting to happen. Regulators are seeing power slipping away between their fingers like sand, and they are going to try to grab it.","news_type":1},"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":884623528,"gmtCreate":1631888101964,"gmtModify":1632805555276,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/884623528","repostId":"2168002520","repostType":4,"isVote":1,"tweetType":1,"viewCount":101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161515051,"gmtCreate":1623934569073,"gmtModify":1634025695477,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment. Thanks !","listText":"Please like and comment. Thanks !","text":"Please like and comment. Thanks !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/161515051","repostId":"1121317952","repostType":4,"repost":{"id":"1121317952","kind":"news","pubTimestamp":1623934346,"share":"https://www.laohu8.com/m/news/1121317952?lang=&edition=full","pubTime":"2021-06-17 20:52","market":"us","language":"en","title":"Goldman-backed SPAC to take Mirion Tech public in $2.6 billion deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1121317952","media":"Reuters","summary":"-Radiation detection provider Mirion Technologies Inc said on Thursday it will go public through a merger with a Goldman Sachs Group Inc-backed special purpose acquisition company, in a deal that values the combined entity at $2.6 billion.The deal with GS Acquisition Holdings Corp II will be supported by a private investment in public equity  of $900 million from investors such as Fidelity Management & Research Company LLC, BlackRock, Neuberger Berman funds and Janus Henderson Investors.PIPE als","content":"<p>-Radiation detection provider Mirion Technologies Inc said on Thursday it will go public through a merger with a Goldman Sachs Group Inc-backed special purpose acquisition company, in a deal that values the combined entity at $2.6 billion.</p>\n<p>The deal with GS Acquisition Holdings Corp II will be supported by a private investment in public equity (PIPE) of $900 million from investors such as Fidelity Management &amp; Research Company LLC, BlackRock, Neuberger Berman funds and Janus Henderson Investors.</p>\n<p>PIPE also includes a $200 million investment from Goldman Sachs.</p>\n<p>Mirion is owned by London-based private equity firm Charterhouse Capital Partners, which revived a sale of the company earlier this year after halting a previous attempt in 2019, according to a report by Bloomberg.</p>\n<p>Charterhouse bought Mirion in 2015 for $750 million.</p>\n<p>Mirion has pursued a string of acquisitions to expand its gamut of services that include detection, measurement and analysis solutions to the nuclear, defence, medical end markets. Its most recent acquisitions include Germany-based Dosimetrics GmbH and Sun Nuclear Corp.</p>\n<p>GS Acquisition, a special purpose acquisition company (SPAC), went public in a $700 million IPO in June last year.</p>\n<p>SPACs are shell companies which raise funds through an initial public offering to take a private company public through a merger at a later date.</p>\n<p>Concerns that SPACs have taken pre-revenue, loss-making electric vehicle makers public at very high valuations have turned PIPE investors away in recent weeks.</p>\n<p>Mirion will list on the New York Stock Exchange under the ticker symbol “MIR”, after the deal closes in the second half of the year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman-backed SPAC to take Mirion Tech public in $2.6 billion deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman-backed SPAC to take Mirion Tech public in $2.6 billion deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://wwww.reuters.com/article/mirion-tech-ma-gs-acquisition/update-1-goldman-backed-spac-to-take-mirion-tech-public-in-2-6-bln-deal-idUSL3N2NZ354><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>-Radiation detection provider Mirion Technologies Inc said on Thursday it will go public through a merger with a Goldman Sachs Group Inc-backed special purpose acquisition company, in a deal that ...</p>\n\n<a href=\"https://wwww.reuters.com/article/mirion-tech-ma-gs-acquisition/update-1-goldman-backed-spac-to-take-mirion-tech-public-in-2-6-bln-deal-idUSL3N2NZ354\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSAH.U":"GS Acquisition Holdings Corp II"},"source_url":"https://wwww.reuters.com/article/mirion-tech-ma-gs-acquisition/update-1-goldman-backed-spac-to-take-mirion-tech-public-in-2-6-bln-deal-idUSL3N2NZ354","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121317952","content_text":"-Radiation detection provider Mirion Technologies Inc said on Thursday it will go public through a merger with a Goldman Sachs Group Inc-backed special purpose acquisition company, in a deal that values the combined entity at $2.6 billion.\nThe deal with GS Acquisition Holdings Corp II will be supported by a private investment in public equity (PIPE) of $900 million from investors such as Fidelity Management & Research Company LLC, BlackRock, Neuberger Berman funds and Janus Henderson Investors.\nPIPE also includes a $200 million investment from Goldman Sachs.\nMirion is owned by London-based private equity firm Charterhouse Capital Partners, which revived a sale of the company earlier this year after halting a previous attempt in 2019, according to a report by Bloomberg.\nCharterhouse bought Mirion in 2015 for $750 million.\nMirion has pursued a string of acquisitions to expand its gamut of services that include detection, measurement and analysis solutions to the nuclear, defence, medical end markets. Its most recent acquisitions include Germany-based Dosimetrics GmbH and Sun Nuclear Corp.\nGS Acquisition, a special purpose acquisition company (SPAC), went public in a $700 million IPO in June last year.\nSPACs are shell companies which raise funds through an initial public offering to take a private company public through a merger at a later date.\nConcerns that SPACs have taken pre-revenue, loss-making electric vehicle makers public at very high valuations have turned PIPE investors away in recent weeks.\nMirion will list on the New York Stock Exchange under the ticker symbol “MIR”, after the deal closes in the second half of the year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":867964587,"gmtCreate":1633188872595,"gmtModify":1633188872947,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Comment and like please.&nbsp; Thanks&nbsp;","listText":"Comment and like please.&nbsp; Thanks&nbsp;","text":"Comment and like please. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/867964587","repostId":"1134305481","repostType":4,"repost":{"id":"1134305481","kind":"news","pubTimestamp":1633152909,"share":"https://www.laohu8.com/m/news/1134305481?lang=&edition=full","pubTime":"2021-10-02 13:35","market":"hk","language":"en","title":"3 Stocks That Can Double Again in the Fourth Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=1134305481","media":"The motley fool","summary":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this mo","content":"<p>Key Points</p>\n<ul>\n <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>\n <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>\n <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li>\n</ul>\n<p></p>\n<p>It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p>\n<p><b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b>&nbsp;(NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p>\n<p>1. Crocs</p>\n<p>Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p>\n<p>The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p>\n<p>The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p>\n<p>Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p>\n<p>2. AMC Entertainment</p>\n<p>You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p>\n<p>However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p>\n<p>Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p>\n<p>3. Upstart</p>\n<p>I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p>\n<p>Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p>\n<p>With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Can Double Again in the Fourth Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Can Double Again in the Fourth Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-02 13:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CROX":"卡骆驰","UPST":"Upstart Holdings, Inc.","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134305481","content_text":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.\nUpstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.\n\n\nIt's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?\nCrocs (NASDAQ:CROX),AMC Entertainment(NYSE:AMC), andUpstart (NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.\n1. Crocs\nRemember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.\nThe comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.\nThe year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?\nDespite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.\n2. AMC Entertainment\nYou may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.\nHowever, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?\nFundamentally speaking, the catalysts are also there.Shang-Chi and the Legend of the Ten Ringsshattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.\n3. Upstart\nI love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.\nGrowth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.\nWith Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.","news_type":1},"isVote":1,"tweetType":1,"viewCount":182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":886242582,"gmtCreate":1631599857546,"gmtModify":1631890053127,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment. Thanks&nbsp;","listText":"Please like and comment. Thanks&nbsp;","text":"Please like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/886242582","repostId":"1141290411","repostType":4,"isVote":1,"tweetType":1,"viewCount":114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":884629074,"gmtCreate":1631888020998,"gmtModify":1632805556372,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/884629074","repostId":"1171574345","repostType":4,"isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810852348,"gmtCreate":1629965781884,"gmtModify":1633681135428,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/810852348","repostId":"1170918709","repostType":4,"repost":{"id":"1170918709","kind":"news","pubTimestamp":1629965646,"share":"https://www.laohu8.com/m/news/1170918709?lang=&edition=full","pubTime":"2021-08-26 16:14","market":"us","language":"en","title":"Square’s Foray In The BNPL Sector Will Continue Powering SQ Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1170918709","media":"InvestorPlace","summary":"Square's acquisition of Afterpay has expanded its growth runway incredibly and should be a major catalyst for SQ stock","content":"<p>Fintech giant&nbsp;<b>Square</b>(NYSE:<b><u>SQ</u></b>) has the industry buzzing&nbsp;with its acquisition of the top Australian&nbsp;buy now, pay later (BNPL) company&nbsp;<b>Afterpay</b>(OTCMKTS:<b><u>AFTPY</u></b>). Square will find it easier to scale its business and become an even bigger financial juggernaut with this acquisition. Moreover, its stellar earnings results suggest that there is still a massive growth runway ahead for SQ stock and its underlying business.</p>\n<p>SQ stock has had a topsy turvy run at the stock market since the beginning of the year. It went as low as $191 per share and as high as $289 per share in early August. The stock is up more than 8% and seems to be building up decent momentum after several positive events. It currently trades at just 6.4 times forward sales which is reasonable considering its monstrous growth rates. Therefore, the stock is a buy at present levels for the long term.</p>\n<p><b>Blowout Second Quarter Earnings</b></p>\n<p>The Afterpay acquisition has overshadowed Square’s stellar second-quarter earnings. Once again, the quarter exhibited the strength of the company’s Seller and Cash App ecosystems. Revenues for the quarter&nbsp;shot up to $4.68 billion, including&nbsp;<b>Bitcoin</b>(CCC:<b><u>BTC-USD</u></b>) payment volumes, up 143% from the prior-year period. Even without factoring in Bitcoin payments, its&nbsp;net revenue of $1.96 billion&nbsp;rose 87% on a year-over-year basis. Another encouraging element is its subscription and services-based revenue, which nearly doubled to $685 million during the quarter.</p>\n<p>Furthermore, the Seller and Cash App gross profit margins&nbsp;grew by 85% and 94%, respectively, from the same quarter last year. Its customers continue to find more value in the platform’s ecosystem and bring more funds into Cash App. Moreover, with the slowdown in operating expenses, the adjusted EBITDA&nbsp;was at a healthy $360 million, an improvement of 268% from the prior-year period.</p>\n<p>Square has expressed caution on its short-term performance and did not publish full-year projections. It estimates a&nbsp;212% year-over-year growth&nbsp;in gross profits for Cash App compared to the third quarter of 2020. On the flip side, it expects only a 12% gross profit increase for its &nbsp;Seller ecosystem. However, with the Covid 19 crisis improving, small businesses will continue to flourish, resulting in higher revenues on the seller side.</p>\n<p><b>Afterpay Acquisition</b></p>\n<p>Square acquired Afterpay, which enables them to spread their tentacles into the blossoming BNPL market. It enables consumers to effectively manage their installments directly in Cash App and discover merchants and other BNPL activities. The company CFO, Amrita Ahuja, states that “The plan is for Square to integrate Afterpay into both its consumer Cash App, and its Seller product for small businesses.”</p>\n<p>Hence, Square will be able to supercharge BNPL payment options, offering more flexibility for its consumers. Afterpay will be available on both Seller and Cash App ecosystems.&nbsp;Afterpay earns money on merchant fees and any late fees associated with missed payments. Therefore, it fosters a new revenue source for Square by offering an interest-free alternative to credit cards.</p>\n<p>Afterpay already has 100,000 merchants serving over 16 million customers. The Cash App user base exceeds over 70 million and is likely to experience surge inactivity. Square estimates the global payments opportunity stands&nbsp;at $10 trillion, and BNPL’s penetration rate is just at 2%.</p>\n<p><b>Bottomline On SQ Stock</b></p>\n<p>Square has been killing it off-late with its foray into the BNPL space, its spectacular earnings, and the inception of its bank. These developments will enable the company to expand its customer base to new highs. Moreover, the acquisition of Afterpay will provide synergies and scale, which will boost both its Cash App and Seller platform. Therefore, SQ stock is certainly the pick of the fintech firms at this time, with an incredible future ahead.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Square’s Foray In The BNPL Sector Will Continue Powering SQ Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSquare’s Foray In The BNPL Sector Will Continue Powering SQ Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 16:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/squares-foray-in-the-bnpl-sector-will-continue-powering-sq-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fintech giant Square(NYSE:SQ) has the industry buzzing with its acquisition of the top Australian buy now, pay later (BNPL) company Afterpay(OTCMKTS:AFTPY). Square will find it easier to scale its ...</p>\n\n<a href=\"https://investorplace.com/2021/08/squares-foray-in-the-bnpl-sector-will-continue-powering-sq-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/08/squares-foray-in-the-bnpl-sector-will-continue-powering-sq-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170918709","content_text":"Fintech giant Square(NYSE:SQ) has the industry buzzing with its acquisition of the top Australian buy now, pay later (BNPL) company Afterpay(OTCMKTS:AFTPY). Square will find it easier to scale its business and become an even bigger financial juggernaut with this acquisition. Moreover, its stellar earnings results suggest that there is still a massive growth runway ahead for SQ stock and its underlying business.\nSQ stock has had a topsy turvy run at the stock market since the beginning of the year. It went as low as $191 per share and as high as $289 per share in early August. The stock is up more than 8% and seems to be building up decent momentum after several positive events. It currently trades at just 6.4 times forward sales which is reasonable considering its monstrous growth rates. Therefore, the stock is a buy at present levels for the long term.\nBlowout Second Quarter Earnings\nThe Afterpay acquisition has overshadowed Square’s stellar second-quarter earnings. Once again, the quarter exhibited the strength of the company’s Seller and Cash App ecosystems. Revenues for the quarter shot up to $4.68 billion, including Bitcoin(CCC:BTC-USD) payment volumes, up 143% from the prior-year period. Even without factoring in Bitcoin payments, its net revenue of $1.96 billion rose 87% on a year-over-year basis. Another encouraging element is its subscription and services-based revenue, which nearly doubled to $685 million during the quarter.\nFurthermore, the Seller and Cash App gross profit margins grew by 85% and 94%, respectively, from the same quarter last year. Its customers continue to find more value in the platform’s ecosystem and bring more funds into Cash App. Moreover, with the slowdown in operating expenses, the adjusted EBITDA was at a healthy $360 million, an improvement of 268% from the prior-year period.\nSquare has expressed caution on its short-term performance and did not publish full-year projections. It estimates a 212% year-over-year growth in gross profits for Cash App compared to the third quarter of 2020. On the flip side, it expects only a 12% gross profit increase for its  Seller ecosystem. However, with the Covid 19 crisis improving, small businesses will continue to flourish, resulting in higher revenues on the seller side.\nAfterpay Acquisition\nSquare acquired Afterpay, which enables them to spread their tentacles into the blossoming BNPL market. It enables consumers to effectively manage their installments directly in Cash App and discover merchants and other BNPL activities. The company CFO, Amrita Ahuja, states that “The plan is for Square to integrate Afterpay into both its consumer Cash App, and its Seller product for small businesses.”\nHence, Square will be able to supercharge BNPL payment options, offering more flexibility for its consumers. Afterpay will be available on both Seller and Cash App ecosystems. Afterpay earns money on merchant fees and any late fees associated with missed payments. Therefore, it fosters a new revenue source for Square by offering an interest-free alternative to credit cards.\nAfterpay already has 100,000 merchants serving over 16 million customers. The Cash App user base exceeds over 70 million and is likely to experience surge inactivity. Square estimates the global payments opportunity stands at $10 trillion, and BNPL’s penetration rate is just at 2%.\nBottomline On SQ Stock\nSquare has been killing it off-late with its foray into the BNPL space, its spectacular earnings, and the inception of its bank. These developments will enable the company to expand its customer base to new highs. Moreover, the acquisition of Afterpay will provide synergies and scale, which will boost both its Cash App and Seller platform. Therefore, SQ stock is certainly the pick of the fintech firms at this time, with an incredible future ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":184,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807364718,"gmtCreate":1628001218134,"gmtModify":1633754485852,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and share","listText":"Please like and share","text":"Please like and share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/807364718","repostId":"1145562808","repostType":4,"repost":{"id":"1145562808","kind":"news","pubTimestamp":1628000397,"share":"https://www.laohu8.com/m/news/1145562808?lang=&edition=full","pubTime":"2021-08-03 22:19","market":"us","language":"en","title":"Fed Could Start ‘Tapering’ Soon. Don’t Expect It to Cause Havoc for the Stock Market This Time Around.","url":"https://stock-news.laohu8.com/highlight/detail?id=1145562808","media":"Barron's","summary":"The Federal Reserve is poised to reduce the size of its bond-buying program, so stocks could head lo","content":"<p>The Federal Reserve is poised to reduce the size of its bond-buying program, so stocks could head lower soon. The pain may not be acute, though, because investors generally expect the Fed to do just that.</p>\n<p>It was a different scenario in May 2013, when Ben Bernanke, the Fed’s chief at the time, told Congress that if economic conditions kept improving, and policy makers were confident that would continue, the bank could pare back its buying. Bond yields leapt, and the S&amp;P 500 fell 5% in a five-day stretch in an episode known&nbsp;as the Taper Tantrum.</p>\n<p>As bond yields rose, stocks became relatively less attractive, especially because the bank was signaling it would provide less support to markets and the economy. The Fed ultimately announced a reduction of its buying in December that year.</p>\n<p>This time, investors are already expecting the Fed to taper. The central bank has telegraphed the change in monetary policy on several occasions. Government- bond dealers expect the Fed’s monthly bond purchases, part of its effort to prop up the economy as the pandemic struck, to fall from $120 billion currently to zero by the start of 2023, according to a Goldman Sachs survey.</p>\n<p>Stocks are already valued in a way that makes higher bond yields seem plausible. The S&amp;P 500’s equity-risk premium—the percentage return from earnings and dividends for the average stock on the index, minus the yield on 10-year Treasury debt, is currently at about 6 percentage points, according to Goldman Sachs. The number represents the extra return relative to safe bonds that investors demand for being in equities.</p>\n<p>The figure is higher than the sub 6% levels often seen since 2010, implying that even if bond yields move higher, narrowing the equity-risk premium, stocks would still offer relatively strong returns in historical terms. “Market participants appear aware of tapering,” writes David Kostin, chief U.S. equity strategist at Goldman Sachs. “The equity risk premium remains high versus history.”</p>\n<p>Others agree that markets are pricing in tapering by the Fed. “An orderly and transparent removal of easy monetary policy should not be disruptive, particularly if it’s undertaken in reaction to improvements in the underlying economy, “ wrote Jason Pride, chief investment officer for private wealth at Glenmede.</p>\n<p>At the very least, investors should monitor how much money the Fed pulls out from the bond market and how quickly it does so. A sharp selloff in response to the simple news that the Fed is tapering is far from certain.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fed Could Start ‘Tapering’ Soon. Don’t Expect It to Cause Havoc for the Stock Market This Time Around.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFed Could Start ‘Tapering’ Soon. Don’t Expect It to Cause Havoc for the Stock Market This Time Around.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-03 22:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/federal-reserve-stocks-tapering-51627939038?mod=hp_LEAD_2_B_1><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Federal Reserve is poised to reduce the size of its bond-buying program, so stocks could head lower soon. The pain may not be acute, though, because investors generally expect the Fed to do just ...</p>\n\n<a href=\"https://www.barrons.com/articles/federal-reserve-stocks-tapering-51627939038?mod=hp_LEAD_2_B_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.barrons.com/articles/federal-reserve-stocks-tapering-51627939038?mod=hp_LEAD_2_B_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145562808","content_text":"The Federal Reserve is poised to reduce the size of its bond-buying program, so stocks could head lower soon. The pain may not be acute, though, because investors generally expect the Fed to do just that.\nIt was a different scenario in May 2013, when Ben Bernanke, the Fed’s chief at the time, told Congress that if economic conditions kept improving, and policy makers were confident that would continue, the bank could pare back its buying. Bond yields leapt, and the S&P 500 fell 5% in a five-day stretch in an episode known as the Taper Tantrum.\nAs bond yields rose, stocks became relatively less attractive, especially because the bank was signaling it would provide less support to markets and the economy. The Fed ultimately announced a reduction of its buying in December that year.\nThis time, investors are already expecting the Fed to taper. The central bank has telegraphed the change in monetary policy on several occasions. Government- bond dealers expect the Fed’s monthly bond purchases, part of its effort to prop up the economy as the pandemic struck, to fall from $120 billion currently to zero by the start of 2023, according to a Goldman Sachs survey.\nStocks are already valued in a way that makes higher bond yields seem plausible. The S&P 500’s equity-risk premium—the percentage return from earnings and dividends for the average stock on the index, minus the yield on 10-year Treasury debt, is currently at about 6 percentage points, according to Goldman Sachs. The number represents the extra return relative to safe bonds that investors demand for being in equities.\nThe figure is higher than the sub 6% levels often seen since 2010, implying that even if bond yields move higher, narrowing the equity-risk premium, stocks would still offer relatively strong returns in historical terms. “Market participants appear aware of tapering,” writes David Kostin, chief U.S. equity strategist at Goldman Sachs. “The equity risk premium remains high versus history.”\nOthers agree that markets are pricing in tapering by the Fed. “An orderly and transparent removal of easy monetary policy should not be disruptive, particularly if it’s undertaken in reaction to improvements in the underlying economy, “ wrote Jason Pride, chief investment officer for private wealth at Glenmede.\nAt the very least, investors should monitor how much money the Fed pulls out from the bond market and how quickly it does so. A sharp selloff in response to the simple news that the Fed is tapering is far from certain.","news_type":1},"isVote":1,"tweetType":1,"viewCount":100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179359184,"gmtCreate":1626487987948,"gmtModify":1633926318400,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/179359184","repostId":"1198202103","repostType":4,"repost":{"id":"1198202103","kind":"news","pubTimestamp":1626481985,"share":"https://www.laohu8.com/m/news/1198202103?lang=&edition=full","pubTime":"2021-07-17 08:33","market":"us","language":"en","title":"Dow drops nearly 300 points on Friday, snaps 3-week winning streak","url":"https://stock-news.laohu8.com/highlight/detail?id=1198202103","media":"CNBC","summary":"U.S. stocks fell on Friday, pushing the Dow Jones Industrials Average into the red for the week, as ","content":"<div>\n<p>U.S. stocks fell on Friday, pushing the Dow Jones Industrials Average into the red for the week, as inflation fears overshadowed strong retail sales numbers and better-than-expected earnings reports.\n...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/15/stock-market-open-to-close-news.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow drops nearly 300 points on Friday, snaps 3-week winning streak</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow drops nearly 300 points on Friday, snaps 3-week winning streak\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-17 08:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/15/stock-market-open-to-close-news.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. stocks fell on Friday, pushing the Dow Jones Industrials Average into the red for the week, as inflation fears overshadowed strong retail sales numbers and better-than-expected earnings reports.\n...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/15/stock-market-open-to-close-news.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.cnbc.com/2021/07/15/stock-market-open-to-close-news.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1198202103","content_text":"U.S. stocks fell on Friday, pushing the Dow Jones Industrials Average into the red for the week, as inflation fears overshadowed strong retail sales numbers and better-than-expected earnings reports.\nThe Dow lost 299.17 points, or 0.86%, to close at 34,687.85. The S&P 500 dipped 0.75% to 4,327.16 and the Nasdaq Composite shed 0.8% to 14,427.24.\nThe three averages closed the week lower to each snap 3-week win streaks. The Dow ended the week down 0.52%, while the S&P 500 dipped 0.97% and the Nasdaq Composite fell 1.87% during the same period.\n\nA U.S.consumer sentimentindex from the University of Michigan came in at 80.8 for the first half of July, down from 85.5 last month and worse than estimates from economists, who projected an increase. The report released Friday showed inflation expectations rising, with consumers believing prices will increase 4.8% in the next year, the highest level since August 2008.\nThe Dow gave up its gains early Friday shortly after the University of Michigan report came out 30 minutes into the session. Losses increased as the day went on with major averages closing at the lows of the session.\nThe consumer sentiment weakness “is at face value hard to square with the acceleration in employment growth and the continued resilience of the stock market,” said Andrew Hunter, senior U.S. economist at Capital Economics, but the report “suggested that concerns over surging inflation are now outweighing those positive trends.”\nInflation fears\nThe market was held back all week by inflation fears although the S&P 500 and Dow did touch new all-time highs briefly. On Tuesday, theconsumer price indexshowed a 5.4% increase in June from a year ago, the fastest pace in nearly 13 years.\nStocks got off to a good start Friday with the Dow rising more than 100 points to above 35,000 shortly after the open.Data released before the bell showed retail and food service salesrose 0.6% in June, while economists surveyed by Dow Jones had expected a 0.4% decline. If that level held, it would have been the Dow’s first close ever above 35,000.\nDespite the week’s losses, the Dow is still up 13% for the year and sits just 1.15% from an all-time high. The S&P 500 is up 15% on the year and is 1.51% below its record level.\n“The market looks broadly fairly valued to me, with most stocks priced to provide a market rate of return plus or minus a few percent,” Bill Miller, chairman and chief investment officer of Miller Value Partners,said in an investor letter.\n“There are pockets of what look like appreciable over-valuation and pockets of significant undervaluation in the US market, in my opinion. We can find plenty of names to fill our portfolios and so remain fully invested,” the value investor added.\nEnergy correction\nEnergy stocks, the hottest part of the market in 2021, fell into correction territory on Friday as oil prices pulled back from their highs.\nThe Energy Select Sector SPDR Fund fell more than 2% on Friday, the worst of any group, dropping 14% from its high. Still, the sector is up about 28% in 2021, making it the top performer of any of the 11 main industry groups.\nWeaker performance from technology stocks also weighed on the market Friday. Shares of Apple closed 1.4% lower afternotching a record closejust two days prior. Netflix shares fell ahead of the streaming giant’s second-quarter earnings report next week.\nInvestors digested strong earnings results from the first major week of second-quarter reports. Though some of the nation’s largest companies posted healthy earnings and revenues amid the economic recovery, the reaction in the stock market has so far been muted.\nThe Financial Select Sector SPDR Fund ended the week 1.5% lower despite big profit growth numbers posted by the likes of JPMorgan Chase and Bank of America.\n“Good earnings might have become an excuse for some investors to take profit. And with earnings expectations so high in general, it takes a really big beat for a company to impress,” JJ Kinahan, TD Ameritrade chief market strategist, said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898009724,"gmtCreate":1628437856768,"gmtModify":1633747142951,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment&nbsp;","listText":"Please like and comment&nbsp;","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/898009724","repostId":"2157490509","repostType":4,"isVote":1,"tweetType":1,"viewCount":165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806994165,"gmtCreate":1627622412957,"gmtModify":1633757665523,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment.&nbsp; Thanks&nbsp;","listText":"Please like and comment.&nbsp; Thanks&nbsp;","text":"Please like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/806994165","repostId":"2155135477","repostType":4,"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178209094,"gmtCreate":1626821845318,"gmtModify":1633770800953,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/178209094","repostId":"2152657163","repostType":4,"isVote":1,"tweetType":1,"viewCount":160,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173963548,"gmtCreate":1626601241284,"gmtModify":1633925552718,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and share","listText":"Please like and share","text":"Please like and share","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/173963548","repostId":"1183956332","repostType":4,"isVote":1,"tweetType":1,"viewCount":97,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179340435,"gmtCreate":1626488537627,"gmtModify":1633926310284,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/179340435","repostId":"1169536573","repostType":4,"repost":{"id":"1169536573","kind":"news","pubTimestamp":1626448731,"share":"https://www.laohu8.com/m/news/1169536573?lang=&edition=full","pubTime":"2021-07-16 23:18","market":"us","language":"en","title":"Coupa Shares Extend Losses After Post-Analyst Day Selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=1169536573","media":"Thestreet","summary":"Coupa Software traded lower for a second day Friday, extending Thursday's near 10% loss, as analysts reassessed their outlooks for the financial management software company following a disappointing analyst day event.Coupa hosted a virtual analyst day on Thursday, when the platform provider shared additional detail about its Coupa Pay service, and also provided an update on its longer-term prospects.Analysts honed in on the more conservative outlook provided by Coupa's management team as the lik","content":"<p>Coupa Software(<b>COUP</b>)&nbsp;traded lower for a second day Friday, extending Thursday's near 10% loss, as analysts reassessed their outlooks for the financial management software company following a disappointing analyst day event.</p>\n<p>Coupa hosted a virtual analyst day on Thursday, when the platform provider shared additional detail about its Coupa Pay service, and also provided an update on its longer-term prospects.</p>\n<p>Analysts honed in on the more conservative outlook provided by Coupa's management team as the likely reason behind Thursday's selloff, though were generally sanguine about the company's longer-term prospects, with Piper Sandler one of the the few Wall Street investment firms to lower its one-year price target.</p>\n<p>Piper Sandler analysts also focused on lack of progress with Coupa Pay, noting that “… considering the necessary conservatism that is needed to continue the well-known beat and raise cadence, the set-up was always less than ideal.” They held their overweight rating on the stock though lowered their price target to $295 from $300.</p>\n<p>Truist Securities was slightly more upbeat, though admitted investors “could have been disappointed by either what they heard from an attach rate perspective on Coupa Pay or potentially were disappointed that it’s likely a multi-year time line before Coupa Pay really moves the needle.” They held their buy rating and price target of $326.</p>\n<p>Barclays analysts noted that while Coupa couldn’t meet “the very high expectations from the Street” for its Coupa Pay service it is maintaining its positive outlook. The investment bank held its equal weight rating on the shares and one-year price target of $250.</p>\n<p>Coupa shares plunged last monthafter the companyprovided a tepid forecastthat raised questions about its pace of billings growth.&nbsp;A number of analysts cut their price targets on the San Mateo, Calif., based company at the time, even after it reported a surprise profit and better-than-expected revenue forecasts.</p>\n<p>At last check, Coupa shares were down 2.24% at $221.04. The stock has fallen 32.7% year to date.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coupa Shares Extend Losses After Post-Analyst Day Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoupa Shares Extend Losses After Post-Analyst Day Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 23:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/coupa-software-coup-rebound-selloff-analysts><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Coupa Software(COUP) traded lower for a second day Friday, extending Thursday's near 10% loss, as analysts reassessed their outlooks for the financial management software company following a ...</p>\n\n<a href=\"https://www.thestreet.com/investing/coupa-software-coup-rebound-selloff-analysts\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/coupa-software-coup-rebound-selloff-analysts","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169536573","content_text":"Coupa Software(COUP) traded lower for a second day Friday, extending Thursday's near 10% loss, as analysts reassessed their outlooks for the financial management software company following a disappointing analyst day event.\nCoupa hosted a virtual analyst day on Thursday, when the platform provider shared additional detail about its Coupa Pay service, and also provided an update on its longer-term prospects.\nAnalysts honed in on the more conservative outlook provided by Coupa's management team as the likely reason behind Thursday's selloff, though were generally sanguine about the company's longer-term prospects, with Piper Sandler one of the the few Wall Street investment firms to lower its one-year price target.\nPiper Sandler analysts also focused on lack of progress with Coupa Pay, noting that “… considering the necessary conservatism that is needed to continue the well-known beat and raise cadence, the set-up was always less than ideal.” They held their overweight rating on the stock though lowered their price target to $295 from $300.\nTruist Securities was slightly more upbeat, though admitted investors “could have been disappointed by either what they heard from an attach rate perspective on Coupa Pay or potentially were disappointed that it’s likely a multi-year time line before Coupa Pay really moves the needle.” They held their buy rating and price target of $326.\nBarclays analysts noted that while Coupa couldn’t meet “the very high expectations from the Street” for its Coupa Pay service it is maintaining its positive outlook. The investment bank held its equal weight rating on the shares and one-year price target of $250.\nCoupa shares plunged last monthafter the companyprovided a tepid forecastthat raised questions about its pace of billings growth. A number of analysts cut their price targets on the San Mateo, Calif., based company at the time, even after it reported a surprise profit and better-than-expected revenue forecasts.\nAt last check, Coupa shares were down 2.24% at $221.04. The stock has fallen 32.7% year to date.","news_type":1},"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":149136707,"gmtCreate":1625708491909,"gmtModify":1633938143965,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/149136707","repostId":"2149531974","repostType":4,"isVote":1,"tweetType":1,"viewCount":58,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":867967341,"gmtCreate":1633188921928,"gmtModify":1633188922325,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Comment and like please. Thanks&nbsp;","listText":"Comment and like please. Thanks&nbsp;","text":"Comment and like please. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/867967341","repostId":"2172618769","repostType":4,"isVote":1,"tweetType":1,"viewCount":508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":885493195,"gmtCreate":1631807945217,"gmtModify":1631888200784,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/885493195","repostId":"1169233466","repostType":4,"repost":{"id":"1169233466","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631804939,"share":"https://www.laohu8.com/m/news/1169233466?lang=&edition=full","pubTime":"2021-09-16 23:08","market":"us","language":"en","title":"Beyond Meat stock dropped nearly 5% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1169233466","media":"Tiger Newspress","summary":"Beyond Meat stock dropped nearly 5% in morning trading after Piper Sandler downgraded the company to","content":"<p>Beyond Meat stock dropped nearly 5% in morning trading&nbsp;after Piper Sandler&nbsp;downgraded&nbsp;the company to an underweight rating.</p>\n<p><img src=\"https://static.tigerbbs.com/58f2b15e1f14a11787379dd95a4d8eb6\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>Shares of Beyond Meat Inc. took a hit Thursday, after Piper Sandler analyst Michael Lavery turned bearish on the plant-based meat company, citing a weaker growth outlook and concern the outlook for foodservice sales may be overly optimistic.</p>\n<p>Lavery downgraded the stock to underweight, after being at neutral for the past eight months. He cut his price target to $95, which is 14% below Wednesday's closing price, from $120.</p>\n<p>\"Beyond is an early leader in plant-based meat, but we believe its current all-channel retail momentum lags consensus expectations, and our foodservice estimates may be high, too,\" Lavery wrote in a note to clients.</p>\n<p>He estimates that the company's U.S. retail sales fell by about 10% in the third quarter, with multi-outlet with convenience store channel sales down 8% and natural channel sales down 27%.</p>\n<p>\"Beyond's retail sales declines are worse than all of its food peers in our coverage besides B&amp;G Foods,\" Lavery wrote. He rates B&amp;G&nbsp;at neutral.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beyond Meat stock dropped nearly 5% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeyond Meat stock dropped nearly 5% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-09-16 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beyond Meat stock dropped nearly 5% in morning trading&nbsp;after Piper Sandler&nbsp;downgraded&nbsp;the company to an underweight rating.</p>\n<p><img src=\"https://static.tigerbbs.com/58f2b15e1f14a11787379dd95a4d8eb6\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>Shares of Beyond Meat Inc. took a hit Thursday, after Piper Sandler analyst Michael Lavery turned bearish on the plant-based meat company, citing a weaker growth outlook and concern the outlook for foodservice sales may be overly optimistic.</p>\n<p>Lavery downgraded the stock to underweight, after being at neutral for the past eight months. He cut his price target to $95, which is 14% below Wednesday's closing price, from $120.</p>\n<p>\"Beyond is an early leader in plant-based meat, but we believe its current all-channel retail momentum lags consensus expectations, and our foodservice estimates may be high, too,\" Lavery wrote in a note to clients.</p>\n<p>He estimates that the company's U.S. retail sales fell by about 10% in the third quarter, with multi-outlet with convenience store channel sales down 8% and natural channel sales down 27%.</p>\n<p>\"Beyond's retail sales declines are worse than all of its food peers in our coverage besides B&amp;G Foods,\" Lavery wrote. He rates B&amp;G&nbsp;at neutral.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169233466","content_text":"Beyond Meat stock dropped nearly 5% in morning trading after Piper Sandler downgraded the company to an underweight rating.\n\nShares of Beyond Meat Inc. took a hit Thursday, after Piper Sandler analyst Michael Lavery turned bearish on the plant-based meat company, citing a weaker growth outlook and concern the outlook for foodservice sales may be overly optimistic.\nLavery downgraded the stock to underweight, after being at neutral for the past eight months. He cut his price target to $95, which is 14% below Wednesday's closing price, from $120.\n\"Beyond is an early leader in plant-based meat, but we believe its current all-channel retail momentum lags consensus expectations, and our foodservice estimates may be high, too,\" Lavery wrote in a note to clients.\nHe estimates that the company's U.S. retail sales fell by about 10% in the third quarter, with multi-outlet with convenience store channel sales down 8% and natural channel sales down 27%.\n\"Beyond's retail sales declines are worse than all of its food peers in our coverage besides B&G Foods,\" Lavery wrote. He rates B&G at neutral.","news_type":1},"isVote":1,"tweetType":1,"viewCount":189,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882786119,"gmtCreate":1631721056231,"gmtModify":1631890053102,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment thanks&nbsp;","listText":"Please like and comment thanks&nbsp;","text":"Please like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/882786119","repostId":"2167859607","repostType":4,"isVote":1,"tweetType":1,"viewCount":328,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831203859,"gmtCreate":1629328033971,"gmtModify":1633685735794,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment&nbsp;","listText":"Please like and comment&nbsp;","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/831203859","repostId":"2160737181","repostType":4,"isVote":1,"tweetType":1,"viewCount":108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890138817,"gmtCreate":1628086278539,"gmtModify":1633753728696,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579743164156658","authorIdStr":"3579743164156658"},"themes":[],"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/890138817","repostId":"2156060681","repostType":4,"isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}